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 The immune system 
Immune systems are essential defense mechanisms that protect various organisms from all 
kinds of pathogens including bacteria, fungi, parasites and viruses. In multicellular organisms, 
it has the additional function of containing the growth of aberrant cells such as cancer cells. 
Generally, the immune system can be divided into two lines of defense: the innate immune 
system, which can already be found in invertebrates and even non-eucaryotic cells; and the 
adaptive immune system present in vertebrates. The innate immune system is triggered 
within minutes to hours and provides an almost immediate, yet non-specific response to 
invading pathogens, whereas the adaptive immune system takes several days to take full 
effect and is more specific. However, the rapid response of the innate immune system is 
essential to defending against invading pathogens. This is explained by the fact that instead of 
recognizing specific pathogens, it is triggered by a broad variety of molecules found in all kind 
of microbes, so called pathogen-associated molecular patterns (PAMPs). The receptors 
responsible for PAMP recognition are germline-encoded and called pattern recognition 
receptors (PRR). This provides a non-specific defense mechanism recognizing core pathogen 
structures and triggering an almost immediate immune response. In many cases this is enough 
to fight the invader, however, the adaptive immune system is summoned if the system is 
overwhelmed (Murphy et al., 2012). 
The adaptive immune system is the second line of defense and provides a specific pathogen 
recognition mechanism. In contrast to the innate immunity, the adaptive immune system 
evolves over an organism’s lifetime and cannot be inherited. This makes the adaptive immune 
system an immensely powerful defense mechanism, providing the organism with 
immunological memory and protecting it against reinfection with the same pathogen. 
Depending on the severity and type of infection, this protective immunity can last a lifetime. 
The adaptive immune system possesses effector cells called B- and T-cells. They recognize 
diverse pathogenic molecular structures known as antigens. Their antigen binding proteins 
are extremely diverse and are generated in individual cells by recombination of specific gene 
segments. B-cell receptors are located on the cell surface and can directly bind to their 
corresponding antigen. Upon antigen recognition, B-cells start to proliferate and differentiate 
into plasma cells. These are producing soluble antigen binding proteins called 
immunoglobulins (or antibodies), which are secreted to the extracellular space where they 
can bind the corresponding antigen, neutralizing it or promoting an immune response. T-cell 





and do not bind to their corresponding antigen directly. Instead, they recognize antigens 
presented through the major histocompatibility complex (MHC) on the surface of other cells. 
Dendritic cells are an innate immune system cell-type that play a crucial role as professional 
antigen presenting cells (APCs). Once activated they travel to lymphoid tissues to interact with 
naïve B- and T-cells (Murphy et al., 2012). The immune system is critical for fighting invading 
pathogens and maintaining tissue homeostasis, however, it also needs to be tightly regulated 
to ensure proper function and prevent auto-activation. Dysfunction can cause severe tissue 
damage via chronic inflammation or the production of autoantibodies, attacking healthy cells. 
This leads to a huge variety of diseases broadly be categorized into autoinflammatory diseases 
(AIDs), caused by the innate immune system, and systemic autoimmune diseases (ADs), 
involving the adaptive immune system (Doria et al., 2012). 
 The innate immune system 
The innate immune system provides fast acting, non-specific defense mechanisms to 
immediately react upon encountering pathogens, instantly preventing their growth and 
spread inside the body. It provides direct anti-pathogenic effector mechanisms – analogous 
to the adaptive immune system – divided into humoral (body fluid related) and cell mediated 
defense mechanisms. Furthermore, it plays an essential role in the activation of adaptive 
immunity as well as the maintenance of tissue integrity and repair. Physical barriers like the 
skin or the low pH environment in the stomach can also be considered to be part of the innate 
immune system, as they shield the body against pathogens or have anti-microbial properties 
(Murphy et al., 2012). Besides, the skin secretes anti-microbial proteins such as defensins to 
complement the physical barrier properties (Brogden, 2005). 
The humoral component of the innate immune system is activated upon pathogens 
overcoming the physical barrier of the body leading to the production of proteins like 
collectins, ficolins and pentraxins, resulting in opsonophagocytosis or the activation of the 
complement system (Bottazzi et al., 2010; Ma and Garred, 2018). The complement system is 
a central defense mechanism of the humoral innate immune system, and was discovered in 
1896 by Bordet as a heat-labile component of the human serum (Dunkelberger and Song, 
2010). It consists of more than 30 soluble proteins, which can either be found in blood or other 
body fluids (Murphy et al., 2012; Walport, 2001). Upon encountering a pathogen, complement 
proteins accumulate on its surface leading to opsonization and activation of the complement 
system. This initiates the recruitment of phagocytic cells, which on the one hand promote 
inflammation and on the other hand engulf the opsonized pathogen to destroy it. Another 
effector mechanism of the complement system is the formation of a protein complex called 





(Murphy et al., 2012). The second part of the innate immune system is the cellular response, 
which is mainly but not exclusively mediated by highly specialized cell types. Upon pathogen 
recognition these cells secrete a cocktail of different cytokines and chemokines, recruiting 
immune cells from surrounding tissue and bloodstream, which is often accompanied by tissue 
swelling (inflammation). These recruited cell types include monocytes, macrophages, 
granulocytes (neutrophils, basophils, eosinophils and mast cells), and innate lymphoid cells, 
such as natural killer (NK) cells (Murphy et al., 2012). 
Phagocytosis (or other forms of endocytosis), the engulfment and destruction of invading 
microorganisms, is a critical mechanism of the innate immune system. It plays an important 
role in the clearance of apoptotic bodies, being critically required for tissue homeostasis and 
remodeling. Phagocytosis is mainly performed by professional phagocytes like macrophages, 
neutrophils or dendritic cells. Pathogen destruction occurs inside the endolysosomal 
compartment and is facilitated by its uniquely hostile environment including low pH, the 
presence of several hydrolases and antimicrobial proteins like lysozyme. Furthermore, 
production of reactive oxygen species (ROS) by nicotinamide adenine dinucleotide phosphate 
(NADPH) and nitric oxide (NO) by inducible nitric oxide synthase (iNOS) are microbicidal 
mechanisms (Flannagan et al., 2012). Phagocytes are critical for innate immune defense but 
are also involved in activating the adaptive immune system in a two-step approach. Initially, 
contact with the pathogen promotes the release of pro-inflammatory cytokines, recruiting 
lymphoid cells. Subsequently, when the pathogen has been phagocytosed and digested, its 
constituent fragments are presented as antigens to the cells of the adaptive immune system, 
activating them (Flannagan et al., 2012). Apart from directly killing the pathogen, another 
defense mechanism is killing the infected cell by inducing cell death. This can either be 
initiated in a cell-independent fashion or be dependent on cell-to-cell interaction between the 
infected and the killer cell. The cell-independent ‘suicide’ results in either an immunologically 
silent death (apoptosis) or the release of cellular content (pyroptosis and necroptosis) leading 
to the activation of surrounding immune cells and an amplified immune response (Morizot 
and Saleh, 2012). Contact induced cell death on the other hand is mediated by NK cells, which 
unlike other cells of the innate immune system are not derived from myeloid but from 
lymphoid progenitors. They comprise the third largest population of lymphocytes (after B and 
T cells) and do not need pre-stimulation to perform their effector function. NK cells are large 
granular cells with various functions, like killing infected or neoplastic cells. Under steady state 
conditions NK cells are in resting state, however, they start to infiltrate infected or malignant 
tissues upon cytokine induced activation (Mandal and Viswanathan, 2015). The innate 
immune system includes a diverse array of intrinsic restriction factors important for defending 
against viral infections. SAM domain and HD domain-containing protein 1 (SAMHD1) for 





human immunodeficiency virus (HIV) (Yan and Chen, 2012). Another example is the activation 
of 2ʹ-5ʹ-oligoadenylate synthetase (OAS) by viral RNA leading to RNase L activation, which in 
turn is blocking viral replication by degrading ssRNA (Chakrabarti et al., 2011). All in all, the 
innate immune system has evolved diverse mechanisms to immediately defend against 
invading pathogens on a cellular level, which can either directly clear the infection or buy time 
for the adaptive immune system to be activated. 
 Pattern recognition receptors (PRRs) 
In order to be able to respond properly to threats and trigger an appropriate immune 
response, cells have developed diverse detection mechanisms. At first it was thought that 
pathogen recognition is a non-specific process, until a group of proteins called toll-like 
receptors (TLR) was found in the 1990s clearly showing specific recognition of distinct 
molecules. It soon became clear that TLRs are not the only group of germline-encoded pattern 
recognition receptors (PRR), which are able to detect various evolutionary conserved 
pathogen-associated molecular patterns (PAMPs) (Kawai and Akira, 2010). Yet it was not 
known how strong immune responses could be triggered under sterile conditions, for example 
after tissue transplantation or in the course of autoimmune diseases. It turned out, the 
immune system is not only capable of recognizing pathogen derived molecules, but is also 
triggered by cytoplasmic content released from damaged cells, called damage-associated 
molecular patterns (DAMP) (Venereau et al., 2015). The first molecules to be identified as such 
were high mobility group box 1 (HMGB1) and uric acid crystals (Scaffidi et al., 2002; Shi et al., 
2003), however, over the years many other molecules like histones, genomic DNA (Gould et 
al., 2015) and ATP (Idzko et al., 2014) were recognized as DAMPs. This clearly shows that our 
body is not necessarily distinguishing between self and non-self molecules, but is rather 
sensitive to the localization of certain patterns allowing the discrimination between damaged 
and healthy tissue (Amarante-Mendes et al., 2018). Generally, there are four main classes of 
PRR including toll-like receptors (TLRs), NOD-like receptors (nucleotide-binding and 
oligomerization domain like receptors, NLRs), RIG-I like receptors (retinoic acid-inducible 
gene-I-like receptors, RLRs) and C-type lectin receptors (CLRs) (Walsh et al., 2013). Activation 
of these proteins induces a pro-inflammatory immune response, resulting in the release of 
cytokines or the killing of infected cells (Amarante-Mendes et al., 2018). 
The first class of PRRs is the TLR family comprised of TLR1-10 in humans and TLR1-9 as well as 
TLR11-13 in mice. TLRs are type 1 transmembrane proteins and either located in the outer 
cellular membrane or inside the endolysosome. They can recognize quite diverse molecular 
patterns ranging from nucleic acids to bacterial cell wall components (Fitzgerald and Kagan, 





a group of transmembrane and soluble proteins which have a C-type lectin domain and 
recognize a variety of glycans (Chiffoleau, 2018; Walsh et al., 2013). Another key feature of 
classical CLRs is their Ca2+ dependency for ligand recognition, though some CLRs are 
independent of calcium and are therefore referred to as C-type lectin-like receptors (CTLRs). 
In addition to their ability to detect carbohydrates, CTLRS are able to recognize a more diverse 
ligand spectrum including lipids and proteins (Dambuza and Brown, 2015). The third group of 
PRR are RLRs, including the proteins RIG-I (retinoic acid-inducible gene I), MDA5 (melanoma 
differentiation-associated gene 5), and LGP2 (laboratory of genetics and physiology 2) 
(Takeuchi and Akira, 2009; Yoneyama and Fujita, 2008). All RLRs are located in the cytosol and 
recognize RNA, which leads to the release of type I interferons (IFN) as well as pro-
inflammatory cytokines (Yoneyama and Fujita, 2008). RIG-I, for example, was discovered to 
specifically detect viral RNA molecules bearing a 5’-triphosphate end (Hornung et al., 2006; 
Pichlmair et al., 2006). The last group of PRRs are NLRs, which are known to activate the innate 
immune system upon cellular injury or stress (Platnich and Muruve, 2019). All NLRs share a 
similar basic structure consisting of a variable number of C-terminal leucine-rich repeat 
domains (LRR) and a nucleotide-binding and oligomerization (NACHT) domain (Lamkanfi and 
Dixit, 2014). They can be divided into several subgroups with the most important ones being 
NLRCs and NLRPs. They are further distinguished by functional domains like the caspase 
recruitment domain (CARD) in the case of NLRC receptors, or the pyrin domain (PYD), which 
can be found in NLRP proteins (Platnich and Muruve, 2019). Another important feature of 
some NLRs (NLRP3, NLRP1, NLRC4) is their ability to form large multiprotein complexes called 
inflammasomes. They are formed inside the cytosol and result in the activation of the 
proinflammatory caspases 1 and 11 (caspase 4/5 in humans) as well as the release of mature 
IL-1b and IL-18 (Kayagaki et al., 2011; Martinon et al., 2002; Shi et al., 2014). The activated 
caspases can subsequently cleave a number of distinct substrates including GSDMD, which 
leads to pore formation in the outer cellular membrane and a lytic cell death, called pyroptosis 
(Gaidt and Hornung, 2016; Kayagaki et al., 2015; Sborgi et al., 2016; Shi et al., 2015). Apart 
from the four big PRR families, two additional DNA sensing pathways can be found inside the 
cytosol: the cGAS (cyclic GMP AMP synthase) -STING (stimulator of interferon genes) axis; the 
AIM2 inflammasome. Like most other PRRs, activation of the cGAS-STING pathway leads to 
the production of pro-inflammatory cytokines and type I interferons (Ishikawa and Barber, 
2008; Wu et al., 2013). Upon recognition of cytosolic DNA by cGAS, the protein starts to 
produce the second messenger cyclic-GMP-AMP (cGAMP). cGAMP can then travel to the 
endoplasmic reticulum (ER) bound protein STING and activate it. This causes STING to travel 
to the Golgi apparatus where it recruits TBK1 as well as the IKKs initiating downstream 





Additionally, cytosolic DNA can be recognized by the Aim2 inflammasome, leading to 
pyroptotic cell death and the release of IL-1b (Hornung et al., 2009; Unterholzner et al., 2010).  
Upon PRRs recognizing a ligand, different downstream signaling pathways are engaged. One 
of them is leading to the activation of the transcription factor NF-kB, which can travel to the 
nucleus and regulate a huge number of genes modulating the inflammatory immune response 
(Liu et al., 2017). A major protein class regulated by NF-kB are cytokines, a group of small, low 
molecular weight proteins critically involved in the regulation of acute and chronic 
inflammations. Key pro-inflammatory cytokines are interleukin-1 (IL-1), IL-6 or tumor necrosis 
factor (TNF), all signaling via type I cytokine receptors. However, this is not true for all 
cytokines, as IL-8 is for example signaling via G protein-coupled receptors (GPCRs) (Turner et 
al., 2014). As already mentioned, one important cytokine which is also often used as read-out 
for TLR activation is IL-6. It is a soluble glycosylated protein with a size of 21-26 kDa and is 
modulating different cellular processes like the immune response, tissue homeostasis and 
hematopoiesis (Tanaka et al., 2014). The cytokine is mainly produced by monocytes and 
macrophages upon PAMP or DAMP detection, but also downstream of IL-1 or TNF stimulation 
(Tanaka et al., 2014). Nevertheless, it can also be produced by other cell types like 
keratinocytes or fibroblasts (Turner et al., 2014). Once released into the extracellular space, 
IL-6 can bind to the receptor IL-6R, which in turn induces dimerization of the signal transducing 
chain gp130 (Murakami et al., 1993). Downstream of gp130 activation, the JAK-STAT3 (Janus 
kinase - signal transducers and activators of transcription) as well as the JAK-SHP-2-MAPK 
(mitogen-activated protein kinase) pathways are activated (Tanaka et al., 2014). Another very 
important class of cytokines expressed upon PRR activation are type I interferons which are 
playing an important role especially during viral infections. Secreted type I interferons signal 
through a heterodimeric receptor composed of the proteins IFNARI and IFNARII (interferon-
α/β receptor). Upon activation, the receptor is endocytosed and recruits JAK1 and tyrosine 
kinase 2 (TYK2) leading to the phosphorylation of different STAT proteins (mainly STAT1 and 
STAT2). The STAT1/2 heterodimer can then form a complex with IRF9 modulating the 
transcription of IFN-stimulated genes (ISGs) (Chmiest et al., 2016; Ivashkiv and Donlin, 2014; 
Lee and Ashkar, 2018). Interferons can act in a paracrine, autocrine or systemic fashion and 
can for example lead to the transcription of OAS genes as well as the upregulation of MHC II 
proteins and the maturation of dendritic cells (Lee and Ashkar, 2018). 
Besides cytokine release, different forms of induced cell death are powerful tools to control 
infections and modulate the innate as well as the adaptive immune response (Amarante-
Mendes et al., 2018). Generally, regulated cell death can be divided into apoptosis and forms 
of induced necrosis (Tait et al., 2014). Apoptosis was already described in 1972 and is an 





Tait et al., 2014). Besides its important role during immune responses, it is critically involved 
in the control of cell populations during development and aging (Elmore, 2007). Classical 
features of apoptosis are chromatin condensation, nuclear fragmentation and the formation 
of apoptotic bodies, which are normally removed by phagocytic cells (Elmore, 2007; Szondy 
et al., 2017). During this process the cellular contents are kept entirely inside the apoptotic 
bodies, thus it is a non-inflammatory and immunogenic silent form of cell death (Szondy et al., 
2017). Apoptosis is categorized based on whether the initiating signal is derived from 
intracellular or extracellular sources, intrinsic or extrinsic apoptosis respectively. Downstream, 
the initiator caspases (caspase 8 and 9) are activated which in turn can cleave the executioner 
caspases (caspase 3, 6 and 7), leading to cell death (D'Arcy, 2019). In contrast to apoptosis, all 
forms of regulated necrosis lead to the release of cellular contents into the extracellular space, 
which can result in the release of DAMPs and hence activate the innate immune system. A 
well-studied form of regulated necrosis is called pyroptosis and is mediated by inflammatory 
caspases (Caspase 1, 11 in mice and 1, 4, 5 in humans) (Man et al., 2017). Pyroptosis can mainly 
be observed in professional phagocytic cells like macrophages, dendritic cells or neutrophils 
and is initiated downstream of inflammasome activation (Vande Walle and Lamkanfi, 2016). 
Another important form is necroptosis, which is caspase independent and instead executed 
by the activation of RIPK3 and MLKL. It can be induced downstream of TLRs, death receptors 
and interferon (Dhuriya and Sharma, 2018).  
 Toll-like receptors (TLRs) 
The Toll protein from Drosophila was already studied in the 90’s and was found to be involved 
in anti-microbial responses (Lemaitre et al., 1996). Shortly after, the human homolog, today 
known as TLR4, was discovered. It was shown to be a transmembrane protein consisting of an 
extracellular leucine-rich repeat (LRR) domain and a cytoplasmic domain similar to the one of 
IL-1 receptor, today known as TIR (Toll/Interleukin-1 receptor) domain (Medzhitov et al., 
1997). In the following years it was published by three different groups, that TLR4 is 
recognizing lipopolysaccharide (LPS), which is part of the outer membrane of gram-negative 
bacteria (Poltorak et al., 1998; Qureshi et al., 1999; Takeuchi et al., 1999). 
Like it was shown for TLR4, all TLRs are type I integral membrane proteins with a N-terminal 
leucine-rich repeat (LRR) domain, one single transmembrane domain and a TIR domain for 
downstream signaling (Bell et al., 2003; Botos et al., 2011). Ligand binding is mediated by the 
LRR domain, which is built up by leucine-rich repeats, a characteristic repetitive pattern rich 
in leucine and a length of 20-30 residues. When assembled, the domain forms a curved 
horseshoe like structure, mediating protein-protein interactions. Leucine-rich repeats are a 





eukaryotes (Bella et al., 2008). TLRs are used by a huge variety of species including humans 
and mice, which encode 10 and 12 TLRs respectively. Other species like the sea urchin even 
encodes for 222 TLR genes (Imler and Hoffmann, 2002; Satake and Sekiguchi, 2012). TLRs are 
synthesized inside the endoplasmic reticulum (ER) before being transported to either the 
plasma membrane or the endolysosomal compartment. Therefore, it is not surprising that the 
lack of ER localized chaperones like gp96, PRAT4A and Unc93B1 leads to compromised TLRs 
function. Intriguingly, this is not true for TLR3, the reason for which remains elusive (Fitzgerald 
and Kagan, 2020). Unc93B1, for example, is involved in intracellular transport of TLRs, which 
renders it essential for proper receptor function (Kim et al., 2008). Furthermore, binding of 
Figure 1.1 Toll-like receptor signaling pathways 
Toll-like receptors (TLRs) belong to the class of pattern recognition receptors (PRR) and play an important role in 
innate immune defense. TLRs are located either on the cell surface or inside the endolysosomal compartment. 
They are able to recognize a broad spectrum of different molecules, including DNA, RNA and bacterial cell wall 
components like LPS. The receptors consist of a leucine-rich repeat (LRR) domain, one transmembrane domain 
and a TIR domain for downstream signaling. Upon activation all TLRs form a dimer and signal via the adapter 
proteins MyD88 or TRIF, resulting in the activation of diverse signaling pathways. This leads to cell survival, the 





Unc93B1 to the receptors is critically required to maintain stability of the proteins after 
synthesis (Pelka et al., 2018). After reaching the acidic milieu of the endolysosome, TLR3, TLR7, 
TLR8 and TLR9 are cleaved within their leucine-rich-repeat domain (Z-loop), which is mediated 
by various cathepsins (Ewald et al., 2011; Fukui et al., 2018). Uncleaved receptors are unable 
to dimerize, hence the necessity for LRR domain cleavage to occur for TLR activation is 
essential. Nevertheless, the two fragments always stay associated with one another (Ohto et 
al., 2018; Tanji et al., 2016). 
TLRs in humans have evolved to recognize a broad variety of pathogen-associated molecular 
pattern (PAMPs) and can be divided into two groups. One group including TLR1, TLR2, TLR4, 
TLR5 and TLR6, is located at the cell surface and is responsible for recognition of extracellular 
molecules. The second group is localized inside the endolysosomal compartment composed 
of TLR3, TLR7, TLR8 and TLR9 (Satake and Sekiguchi, 2012). One of the TLRs found at the cell 
surface is TLR2, forming a heterodimer with either TLR1 or TLR6 (Jin et al., 2007; Kang et al., 
2009), recognizing lipid containing PAMPs from the extracellular space. Its ligands include 
lipoteichoic acid as well as di- and tri-acetylated cysteine-containing lipopeptides (Takeda et 
al., 2003). As previously mentioned, TLR4 recognizes the bacterial cell wall component LPS. 
For proper signaling it requires the co-receptor MD-2, which is bound to the LRR region of 
TLR4 via several hydrogen bonds (Kim et al., 2007). Furthermore, CD14 is needed to deliver 
LPS to the receptor, however, this can be overcome by high concentrations of LPS. However, 
CD14 is critically required for TLR4 mediated TRIF signaling, which cannot be compensated by 
high LPS concentrations (Zanoni et al., 2011). Interestingly, the potency of endotoxins like LPS 
is significantly dependent on its acetylation status (Teghanemt et al., 2005). The last TLR found 
on the cell surface is TLR5 and in contrast to other TLRs it recognizes a critical protein 
component of bacterial flagella, flagellin (Hayashi et al., 2001). It is mostly expressed in 
intestinal lamina propria cells controlling the microbiota of the gut (Vijay-Kumar et al., 2010). 
An intracellular, endolysosomally located TLR receptor is TLR3, recognizing dsRNA produced 
by most viruses at some point during their life cycle. Under steady-state conditions TLR3 exists 
in a monomeric state, but dimerizes upon recognition of RNA with a length of at least 40-
50 bp. In line with its endolysosomal localization the receptor can only be activated at low pH 
(below pH 6.5) (Leonard et al., 2008). The next receptors found in this acidic milieu of the 
endolysosome are TLR7 and TLR8. Both proteins recognize single stranded RNA (ssRNA) and 
have two distinct binding pockets, for either a single nucleotide or a short RNA fragment 
(Miyake et al., 2017). The two TLRs differ in that TLR7 recognizes guanosine in its first pocket 
and uridine containing ssRNA in its second (Zhang et al., 2016), while TLR8 binds to uridine in 
its first and purine terminated fragments in its second pocket (Tanji et al., 2015). Interestingly, 
for both TLR7 and TLR8, binding of ssRNA to the second pocket seems to enhance the binding 





The last member of the endolysosomal TLR family is TLR9, which recognizes CpG sequences in 
single-stranded DNA (ssDNA). It was shown that DNase II acts upstream of TLR9, generating 
appropriate ligands by cleaving CpG-A into 11-12mer fragments needed for receptor 
activation. Intriguingly, even though the absence of DNase II leads to DNA accumulation inside 
the endolysosome, DNASE2-/- mice show activation of cGAS-STING rather than TLR9 (Chan et 
al., 2015; Okabe et al., 2005). This strongly indicates that in the absence of DNase II, 
accumulated DNA leaks from the endolysosome into the cytoplasm, where it can activate the 
cGAS-STING pathway. To-date, TLR10 is the only member of the TLR family that is poorly 
studied and whose corresponding ligand remains elusive (Fitzgerald and Kagan, 2020). 
Different signaling pathways can be engaged downstream of TLRs, all requiring close proximity 
of the TIR domains via receptor dimerization or conformational change of the preformed 
dimer (Latz et al., 2007; Tanji et al., 2013). Activation of these downstream pathways can lead 
to significant changes in cellular processes like gene transcription, translation, splicing, 
autophagy and glycolysis. Upon TIR domain approximation, a large protein complex, the 
supramolecular organizing center (SMOC), is formed inside the cytosol. Generally, TLRs can 
initiate the formation of either the myddosome or triffosome, which assemble within minutes 
after receptor activation (Fitzgerald and Kagan, 2020). In case of the myddosome, TIR domain 
dimerization is in most cases recognized by a membrane protein called TIRAP (or MAL) leading 
to MyD88 recruitment. However, not all MyD88 dependent responses are TIRAP dependent 
(Bonham et al., 2014; Horng et al., 2002). Apart from MyD88, the myddosome consists of two 
different members of the IRAK family of serine-threonine kinases, IRAK2 and IRAK4. The 
crystal structure revealed that the protein complex is a single stranded left-handed helix of 
death domains (DD), consisting of six MyD88, four IRAK4 and four IRAK2 proteins (Lin et al., 
2010). The C-terminal TIR domain of MyD88 is thereby interacting with the TIR domain of TLRs 
or TIRAP, whereas the N-terminal death domain mediates the binding of IRAKs (Fitzgerald and 
Kagan, 2020). The close proximity of IRAK proteins greatly enhances their 
autophosphorylation, leading to the subsequent recruitment of the E3 ubiquitin ligase TRAF6 
(Cao et al., 1996; Ferrao et al., 2014; Lomaga et al., 1999). Downstream of TRAF6 recruitment, 
the kinase TAK1 gets activated, subsequentially leading to IKK mediated NF-kB activation as 
well as the initiation of MAPK signaling (Emmerich et al., 2013; Wang et al., 2001). 
Furthermore, TRAF6 can recruit TBK1, inducing rapid glycolysis mediated by the AKT kinase 
(Everts et al., 2014; Tan and Kagan, 2019). The second SMOC downstream of TLR signaling is 
the triffosome, which can only be activated after TLR3 or TLR4 activation (Akira and Hoshino, 
2003; Yamamoto et al., 2003). However, TLR3 signaling is exclusively dependent on TRIF, 
whereas TLR4 can signal via both adapter proteins TRIF and MyD88 (Yamamoto et al., 2003). 
Analogous to MyD88-TIRAP, TRAM was reported to be the adapter for TRIF in TLR4 signaling. 





al., 2006). In contrast to TLR4, TLR3 can directly bind TRIF without an additional adapter 
protein (Kawasaki and Kawai, 2014). The first branch of TRIF signaling is activation of the NF-
kB pathway by recruiting TRAF6 and receptor interacting protein kinase 1 (RIPK-1) leading to 
signal transduction via TAK1 (Anwar et al., 2019; Kawai and Akira, 2010). In contrast to MyD88, 
TRIF together with MAVS and STING contains a conserved amino acid sequence (pLxIS), which 
can be phosphorylated by the kinase TBK1 and lead to the activation of IFN signaling. Thus, 
TRIF recruits TRAF3, which in turn recruits TBK1 and IKKe. Upon TRIF phosphorylation IRF3 
gets recruited through its positively charged binding domain, allowing its phosphorylation by 
TBK1. This results in dimerization of IRF3, which facilitates it to travel into the nucleus inducing 
type I IFN expression. TBK1 is, therefore, crucially required but not sufficient for IRF3 
phosphorylation (Liu et al., 2015; Ullah et al., 2016). As interferons are potent regulators of 
innate immunity, they must be tightly regulated to prevent dysfunction like autoimmunity. To 
this end, the pLxIS motif is a critical control mechanism for IFN signaling, however, activation 
of the lysosomal nucleic acid sensors TLR7, TLR8 and TLR9 leads to type I interferon 
production, even though they are not signaling via the adaptor protein TRIF (Fitzgerald and 
Kagan, 2020; Schmacke and Hornung, 2020). Instead, they are published to signal via MyD88, 
lacking the pLxIS motif, and IRF5, which is structurally related to IRF3 and IRF7 (Ban et al., 
2018; Schoenemeyer et al., 2005). Recently, the new protein TLR adaptor interacting with 
SLC15A4 on the lysosome (TASL), which is encoded by the gene CXorf21, was found to be 
involved in interferon signaling downstream of TLR7-9 (Heinz et al., 2020). Interestingly, the 
gene was already associated with the human disease systemic lupus erythematosus (SLE) 
(Bentham et al., 2015; Odhams et al., 2019) and was now found to interact with the 
endolysosomal transporter SLC15A4 (Heinz et al., 2020). SLC15A4 is published to transport 
oligopeptides and the amino acid histidine across the endolysosomal membrane and was 
already shown to be involved in TLR signaling (Blasius et al., 2010; Sisirak et al., 2014) as well 
as to be genetically associated with SLE (Han et al., 2009; Odhams et al., 2019). The recently 
published article proposes that SLC15A4 as well as TASL are both critically required for 
interferon signaling downstream of TLR7-9, whereas ligand interaction, NF-kB activation and 
MAPK pathways are unaffected by their absence. Interestingly, it seems as if this newly 
discovered pathway is independent of SLC15A4 transporter function, suggesting that the 
protein only serves as scaffold. TASL has a pLxIS motif analogous to STING, MAVS and TRIF, 
rendering it the fourth protein involved in type I interferon induction upon nucleic acid sensing 
(Heinz et al., 2020; Liu et al., 2015). Therefore, the following mechanism was suggested: 
downstream of TLR7-9 activation, TASL binds to SLC14A4, gets phosphorylated and recruits 
IRF5, which in turn also gets phosphorylated leading to dimerization. The dimer can then enter 
the nucleus to induce type I IFN transcription. The kinase involved in phosphorylation of TASL 





 ssRNA recognition by TLR7 and TLR8 
As previously mentioned, TLR7 and TLR8 are both localized inside the endolysosome and 
recognize ssRNA. They both consist of a cytoplasmic TIR domain, one transmembrane domain 
and an endolysosomal LRR domain (Botos et al., 2011). As mice are the predominant model 
organisms used to investigate TLRs, TLR8’s inability to be activated by natural ssRNA in mice 
has proven to be an impendence to the thorough investigation of TLR8 compared to TLR7. To 
this end, it was initially believed that murine TLR8 is nonfunctional, however, was shown to 
be activated by a combination of imidazoquinoline compounds and poly-T 
oligodeoxynucleotides (Gorden et al., 2006). 
Nevertheless, some years ago the crystal structure of human TLR8 was solved providing an 
improved understanding of its mode of action (Tanji et al., 2013; Tanji et al., 2015). The crystal 
structure revealed that the N-terminal region of the receptor consists of 26 leucine-rich repeat 
domains (Figure 1.2). Between LRR14 and LRR15 an approximately 40 amino acids long 
Figure 1.2 Domain organization of TLR7 and TLR8 
The receptors TLR7 and TLR8 are build up by a leucine-rich repeat (LRR) domain, one transmembrane domain and 
a TIR domain for downstream signaling. The LRR domain consists of 26 repeats and is either located in the 
extracellular space or the lysosomal lumen. Between LRR 14 and 15 a flexible structure, called Z-loop, can be 
found, which has to be cleaved to allow receptor dimerization. The LRR domain is essential for ligand binding and 





insertion region was found, named the Z-loop. This Z-loop gets cleaved inside the 
endolysosomal compartment, however, the two TLR8 fragments stay associated with one 
another as the b-strands of LRR14 and LRR15 are forming a b-sheet structure (Tanji et al., 
2013). Notably, the uncleaved Z-loop serves an autoinhibitory function – preventing receptor 
dimerization. Therefore, the cleavage of the Z-loop is necessary for TLR8 activation (Tanji et 
al., 2016). Upon ligand binding to the preformed TLR8 dimer, a conformational change is 
induced which brings the TIR domains in close proximity resulting in downstream signaling. 
This stands in contrast to TLR7, which exists in a monomeric state and only dimerizes after 
ligand binding (Tanji et al., 2013). 
TLR8 has two distinct ligand binding pockets located inside the LRR domain. The first pocket 
can be found within the dimerization interface at LRR11-14 in TLR8; and LRR 16*-18* in TLR8*. 
It preferentially binds uridine or small chemical compounds like R848 (Tanji et al., 2013; Tanji 
et al., 2015). The second pocket is located in the concave surface of TLR8 and binds to small 
ssRNA fragments like UG or UUG (Tanji et al., 2015). Interestingly, the ON (UUA)6UU is also 
capable of activating TLR8, indicating that guanosine can also be replaced by adenosine 
(Forsbach et al., 2008). As TLR8 is a homodimer, each binding pocket is present twice. 
Importantly, the occupation of the first binding pocket by small chemical compounds like R848 
is sufficient for receptor activation. However, the affinity of uridine is not high enough to 
directly bind the first pocket under physiological conditions. Hence, the second pocket must 
be initially occupied to increase the first pocket’s binding affinity for uridine ultimately leading 
Figure 1.3 Crystal structure of human TLR8 
The crystal structure of the human TLR8 homodimer is shown. The first binding pocket of TLR8 is bound to uridine 
(green), whereas the second one is occupied by a UG dinucleotide (red). Of note, as it is a dimer each binding site 





to receptor activation. The binding affinity of compounds like R848 on the other hand is high 
enough to overcome the need of a second pocket ligand allowing the direct activation of the 
receptor (Tanji et al., 2015). Intriguingly, an un-cleavable Z-loop that keeps TLR8 at a 
monomeric state, still results in binding of short ssRNA fragments at the second but not at the 
first binding site. This can easily be explained by the fact that the first pocket is located within 
the dimerization interface and can only be occupied upon dimerization (Tanji et al., 2016). A 
similar effect was observed for TLR9, which can only dimerize upon Z-loop cleavage but can 
bind to agonistic DNA in an uncleaved state (Ohto et al., 2015). 
The second endolysosomal protein recognizing ssRNA is TLR7. Unlike TLR8, which exists as 
preformed dimer, TLR7 only dimerizes upon ligand binding (Petes et al., 2017). The receptor 
has two distinct binding pockets, one for single nucleotides and one for short ssRNA fragments 
(Zhang et al., 2016). However, in contrast to TLR8 the first pocket is occupied by guanosine, 
not uridine (Shibata et al., 2016; Tanji et al., 2015). Nevertheless, the first pocket of TLR7 and 
TLR8 exhibits homology in amino acid sequence and structure (72 % similarity). This explains 
why both TLR7 and TLR8 can be activated by the same imidazoquinoline compounds (Zhang 
et al., 2016). Analogous to TLR8, guanosine is not capable of efficiently activating TLR7 on its 
own (Lee et al., 2003; Shibata et al., 2016), but relies on the binding of ssRNA to the second 
pocket (Zhang et al., 2016). This initial binding of ssRNA dramatically increases the affinity of 
Figure 1.4 Activation mechanism of human TLR7 
Under steady-state conditions human TLR7 exists in a monomeric state. Generally, ligand binding to the first 
pocket of TLR7 was shown to be necessary and sufficient for receptor activation. However, this is only true for 
chemical compounds like R848, which have a very high affinity towards the first binding site of TLR7. Under 
physiological conditions, ligand binding to the second pocket is essential to increase the affinity of guanosine 
towards the fist pocket. The binding of guanosine leads to receptor dimerization and downstream signaling 
(release of pro-inflammatory cytokines and IFN). 





guanosine towards the first pocket of TLR7 enabling receptor activation. Interestingly, binding 
of chemical compounds like R848 to the first pocket is sufficient to initiate TLR7 dimerization. 
In contrast to the first binding site, which is located at the same position for TLR7 and TLR8, 
the position and structure of the second pocket is distinct. While in TLR8 it is located 
completely outside the dimerization interface, TLR7’s second pocket is close to the 
dimerization site (Zhang et al., 2016). Due to the TLR7 first binding site’s capacity to be 
occupied by deoxyguanosine (dG) in addition to guanosine, TLR7 is capable of recognizing DNA 
degradation, provided ssRNA has already occupied the second pocket (Shibata et al., 2016). 
RNA modifications like methylation or hydroxylation are very common in eukaryotes. RNA 
molecules especially heavily modified are tRNA and rRNA (de Crecy-Lagard et al., 2019; Taoka 
et al., 2018), suggesting that RNA modifications could be critically involved in self versus non-
self-discrimination. In line with this notion, RNA modifications like pseudouridine (Y), 5-
methyluridine (m5U) or N6-methyladenosine (m6A) drastically reduce TLR7 and TLR8 
activation (Kariko et al., 2005). Yet, other RNA modifications like 8-hydroxyguanosine (8-OHG) 
or 8-hydroxydeoxyguanosine (8-OHdG) are able to activate TLR7 in the presence of ssRNA 
(Shibata et al., 2016). Intriguingly, 8-hydroxylation of guanosine is the most prominent natural 
DNA modification induced by reactive oxygen species (ROS) (Wiseman and Halliwell, 1996). 8-
OHdG modifications on the other hand, turn DNA resistant to TREX1 degradation leading to 
DNA accumulation inside the cell. However, despite its resistance, the modified DNA 
eventually releases 8-OHdG, which can be recognized by TLR7 (Gehrke et al., 2013; Kroese and 
Scheffer, 2014). This suggests that modifications like 8-OHG and 8-OHdG play an important 
role in TLR7 activation under oxidative stress conditions (Shibata et al., 2016). Furthermore, 
even if 8-OHdG modified DNA is resistant to degradation, it can still be recognized by the 
cytosolic DNA sensor STING (Gehrke et al., 2013). 
 Endolysosomal TLRs in autoimmunity 
The recognition of pathogens by PRRs like TLRs, is an essential feature in all different forms of 
life to fight invading microbes by triggering an immune response. Thus, it is equally important 
to tightly control these defense mechanisms to avoid excessive activation resulting in 
disrupted immune homeostasis and all kinds of inflammatory and autoimmune diseases such 
as SLE, infection-associated sepsis, atherosclerosis or asthma (Gao et al., 2017; Marshak-
Rothstein, 2006; Tsujimoto et al., 2008). To this end, TLRs became an important drug target 
trying to control these diseases by either interfering with ligand binding, or intracellular 





SLE is one of the main systemic autoimmune disease with a compelling worldwide impact 
across all age and ethical groups (Stojan and Petri, 2018). It is a complex disease defined by 
the recognition of self-antigens and increased type I interferon release, leading to the 
production of autoantibodies attacking healthy tissue (Gao et al., 2017). SLE prevalence is 
highly biased toward women (9:1) and is typically observed at the age of 16-55 years (Scofield 
et al., 2008). It leads to a broad variety of clinical symptoms that can affect almost all organs 
and tissues including fever, mucocutaneous lesions, malar rash and arthritis (Cojocaru et al., 
2011; Tamirou et al., 2018). Although SLE is a complex disease, it is strongly associated with 
endolysosomal TLR activation. It was shown that in the course of SLE, TLR7 and TLR9 are 
detecting autoantigens like endogenous nucleic acids, which leads to the activation of immune 
cells including DC and autoreactive B-cells (Santiago-Raber et al., 2009). Additionally, the 
overexpression of TLR7 in several mouse models causes severe autoimmune phenotypes 
(Celhar et al., 2012), whereas TLR7 deletion results in the decrease of autoantibodies and pro-
inflammatory cytokines production (Gao et al., 2017). Furthermore, recent studies uncovered 
a link between SLE and the protein CXorf21 (TASL), which was now found to be critically 
involved in interferon signaling via the endolysosomal receptors TLR7-9 (Heinz et al., 2020; 
Odhams et al., 2019). The critical involvement of TLR7 in the course of SLE can also partly 
explain the much higher incidence in women, by an X-chromosome gene-dose effect (Scofield 
et al., 2008). Despite the similar mode of action between TLR7 and TLR8, not many studies 
have been published investigating the role of TLR8 in SLE. It was, however, shown that TLR8 
deletion leads to accelerated autoimmunity in lupus-prone mice (Tran et al., 2015; Wu et al., 
2015). Apart from SLE, the overactivation of TLR7 by endogenous RNAs like the micro RNA let-
7 can cause severe damage to the central nervous system (CNS). Intriguingly, the amount of 
let-7b is increased in the cerebrospinal fluid (CSF) of patients suffering from Alzheimer’s 
disease (Lehmann et al., 2012). 
 The RNase T2 superfamily 
As a consequence of their involvement in many cellular processes such as DNA replication, 
control of gene expression and the defense against invading pathogens, RNases play an 
important role in prokaryotes and eukaryotes. A subset of theses RNases, which are either 
secreted into the extracellular space or can be found inside the endolysosomal compartment 
and the vacuole, are cleaving their substrates via a 2’-3’ cyclic phosphate intermediate 
(MacIntosh, 2011). Generally speaking, this set of RNases can, according to their properties, 
be classified into three superfamilies: RNase T1, RNase T2 and RNase A (Irie, 1999). In contrast 
to RNaseT1 and RNase A proteins, RNase T2 enzymes can, due to their diversity, not be 





amino acid sequence is very conserved throughout all members of this family (MacIntosh, 
2011). Interestingly, at least one protein of the RNase T2 family can be found in nearly every 
eukaryote as well as in many bacteria and viruses. The only organisms missing RNase T2 
enzymes are archaea (Condon and Putzer, 2002). The size of RNase T2 family members ranges 
from 19 to 97 kDa, however, the majority has a mass between 20 and 40 kDa and consists of 
a single polypeptide chain (Deshpande and Shankar, 2002). Yet, there are some exceptions 
like Erns from the classical swine fever virus (CSFV), which are multimeric proteins (Schneider 
et al., 1993). Another feature of RNase T2-like enzymes is their glycosylation pattern – the 
most common modification is N-glycosylation of the motif Asn-X-Thr/Ser (Deshpande and 
Shankar, 2002), whereas O-glycosylation is rarely observed (Inokuchi et al., 2000). Enzymes 
from the RNase T2 family cannot be inhibited by EDTA as they are not metalloenzymes. 
Nevertheless, some bivalent metal ions like Zn2+ or Cu2+ are potent inhibitors of human 
RNase T2, whereas Mg2+, Ni2+, and Co2+ have no effect (Thorn et al., 2012). Several crystal 
structures of RNase T2 proteins like MC1 from bitter ground (Nakagawa et al., 1999) or 
EcRNase I from E. coli are available and despite their low sequence similarity, all of them have 
a core of hydrophobic residues at comparable locations (Deshpande and Shankar, 2002; 
Rodriguez et al., 2008). Analysis of the different crystal structures revealed a high level of 
conservation only for residues located at the active center of the enzymes (MacIntosh, 2011). 
All RNase T2 enzymes belong to the class of transferase-type endoribonucleases and cleave 
their substrates via a 2’-3’-cyclic phosphate intermediate state, before hydrolyzing it to a 3’-
phosphate (Figure 1.4) (Irie, 1999; Tanaka et al., 2000). Yet, some members of the T2 family 
were also reported to mainly generate 2’-3’-terminated fragments as a final product (Chacko 
and Shankar, 1998; Nurnberger et al., 1990). The cleavage mechanism was mostly studied for 
fungal enzymes, however, the high level of conservation between the active sites of known 
enzymes suggests a similar mode of action for all members of the RNase T2 family. It was 
shown that two histidine residues within the active center of the proteins are essential for 
enzymatic function (Kawata et al., 1990; Parry et al., 1997). They are located at two particularly 
conserved regions, the CAS I (conserved active site) and CAS II site, with the amino acid 
sequence F/WTL/IHGLWP and FWXHEWXKHGTC, respectively (Irie, 1999). According to 
RNase A nomenclature the active center of the enzyme was named P1 site, which is flanked 
by two nucleotide binding pockets, called B1 and B2 (MacIntosh, 2011). Most RNase T2 
enzymes do not have a substrate specificity, however, some members preferentially cleave 
between two specific bases (Deshpande and Shankar, 2002). Although at least one member 
of the RNase T2 family can be found in nearly all kingdoms of life, the proteins seem to be 
particularly widespread in plants, resulting in a huge variety and number of gene duplications. 
Hence, plant enzymes can be divided into three classes: class I enzymes, a diverse group of 





enzymes correspond to S-RNases, seeming to share a common ancestor which originated from 
a class I enzyme (Igic and Kohn, 2001; Roalson and McCubbin, 2003; Steinbachs and Holsinger, 
2002); and class II enzymes, which are much more conserved, resulting in usually only one 
copy per genome. The high level of conservation of class II proteins suggests, that these 
enzymes are involved in essential cellular processes like housekeeping (MacIntosh et al., 
2010). In contrast to plants, only one member of the RNase T2 family can be found in most 
animals including humans (Hillwig et al., 2009). This could indicate, that RNase T2 enzymes in 
vertebrates are comparably involved in housekeeping functions to class II RNases from plants 
(MacIntosh, 2011). 
The functions of RNase T2 enzymes are quite diverse and include tasks like housekeeping, 
rRNA degradation and antimicrobial defense (MacIntosh, 2011). Some plants such as 
Solanaceae, Scrophulariaceae, and Rosaceae use S-RNases to assure self-incompatibility and 
prevent self-pollination. To this end, the plants have S-RNases in the pistils and the S-locus F-
box (SLF) protein in the pollen. If the haplotype of the pollen matches the one of the pistil, it 
is recognized as self-pollen and fertilization is prevented (Kumar and McClure, 2010; Meng et 
al., 2011). Other plant RNases were published to have antimicrobial features namely, 
RNase NE from tobacco plants is thought to be involved in the defense against Phytophthora 
parasitica and Fusarium oxysporum (Hugot et al., 2002). Furthermore, it was suggested that 
RNases can provide antimicrobial activities in nectar (Hillwig et al., 2010). Nevertheless, other 
members of the RNase T2 family have functions independent of their catalytic activities: Rny1 
for example, the only member of the RNase T2 superfamily present in Saccharomyces 
cerevisiae, is not only involved in cytotoxic responses and the cleavage of tRNA and rRNA, but 
can also induce cell death independent of its catalytic activity (MacIntosh et al., 2001; 
Thompson and Parker, 2009). Interestingly, some RNase T2 enzymes are even thought to have 
tumor suppression functions, although the mechanism is not understood (MacIntosh, 2011). 
Figure 1.5 Phosphate configurations at the 3’ end of RNA 
The most common phosphate configuration after cleavage is the open 3’ phosphate (right panel). However, some 





Only one member of the RNase T2 family, called RNase T2, is expressed in humans. It is 
composed of seven a-helices and eight b-strands building a central b-sheet structure. It has 
four essential disulfide bonds between the cysteine residues 48/55, 75/121, 184/241 and 
202/213. Furthermore, the protein is glycosylated at the asparagine residues 76, 106 and 212. 
As already mentioned, the protein can be inhibited by zinc and copper ions, however, its 
catalytic activity is independent of its glycosylation status (Thorn et al., 2012). The structure 
of human RNase T2 is related to RNase LE from Solanum lycopersicum (Tanaka et al., 2000), 
RNase MC from Momordica charantia (Nakagawa et al., 1999; Numata et al., 2003) and RNase 
NW from Nicotiana glutinosa (Kawano et al., 2002). Analysis revealed that the core structure 
harboring the active center of the protein is very conserved between species, whereas the 
outer loops are rather variable (Thorn et al., 2012). Loss-of-function mutations in human 
RNase T2 leads to severe diseases mimicking an congenital cytomegalovirus (CMV) brain 
infection. The MRI of such patients shows multifocal white matter lesions and in rare cases 
calcifications, leading to impairment, spasticity and sometimes epilepsy (Henneke et al., 
2009). A transgenic zebrafish model showed comparable brain abnormalities together with 
RNA accumulation in the lysosomal compartment of cerebral neurons (Haud et al., 2011). 
Most known clinically relevant mutations have severe impact on the protein conformation - 
the C184R mutation for example disrupts the disulfide bond between cysteine 184 and 241, 
whereas most other mutations result in altered mRNA splicing leading to a disrupted a-b-core 
motif (Thorn et al., 2012). 
 The RNase A superfamily 
The second big family of RNases is the RNase A superfamily. The protein RNase A was 
originally purified from bovine pancreatic tissue and is one of the best studied mammalian 
proteins. Over time, other closely related RNases were discovered in mammalians and other 
vertebrates, becoming the first members of the RNase A superfamily (Koczera et al., 2016). All 
members of this family are stabilized by several disulfide bonds and have two catalytic 
histidines (H) as well as one lysine (K), which are located within the CKXXNTF motif. RNase A 
enzymes do not have a common substrate specificity but seem to preferentially cleave 
pyrimidines (Raines, 1998). The enzymes efficiently cut ssRNA, however, some members of 
this family, including human RNase 1, also very potently cut dsRNA and even DNA-RNA hybrids 
(Potenza et al., 2006; Sorrentino, 2010). Generally, 13 representatives of the RNase A family 
can be found in humans (RNase 1-13) (Gupta et al., 2013). These enzymes play an important 
role in many different cellular processes like antiviral, antibacterial and antifungal defense as 
well as cytotoxic activities. The canonical RNase A proteins (RNase 1-8), secreted by several 





immunomodulatory functions (Boix and Nogues, 2007; Gupta et al., 2013; Martin et al., 2016). 
RNases 9-13 on the other hand seem to be involved in male reproductive functions (Cho et 
al., 2005). Of note, all human RNase A proteins are single exon genes and are all located on 






2 Aims of this work 
The central dogma of innate immune defense is the recognition of all kinds of PAMPs, DAMPs 
and MAMPs by cellular pattern recognition receptors. The detection of RNA molecules is 
especially essential for the defense against a broad variety of viral and bacterial infections. 
Thus, several PRRs are located in different cellular compartments to ensure proper RNA 
recognition, including MDA5 and RIG-I, located inside the cytoplasm (Hornung et al., 2006; 
Kato et al., 2006), as well as TLR7 and TLR8, which can be found in the endolysosomal 
compartment. The recently solved crystal structures of TLR7 and TLR8 revealed two distinct 
RNA binding pockets for either receptor. It was shown that the first pocket binds a single 
nucleotide (uridine for TLR8 and guanosine for TLR7), whereas the second one recognizes at 
least di- or trinucleotides (Tanji et al., 2015; Zhang et al., 2016). However, the exact substrate 
specificity as well as the activation mechanism of either receptor is not fully understood. This 
is especially true since most foreign RNA molecules entering the cell are complex in sequence 
and therefore not suitable ligands for TLR7 or TLR8 activation. Furthermore, TLR8 is 
particularly poorly studied as ssRNA ligands cannot activate the receptor under physiological 
conditions in murine models (Gorden et al., 2006; Hemmi et al., 2002). Analogous to TLR9 
whereby DNase II generates appropriate ligands upstream of the receptor (Chan et al., 2015), 
it is tempting to assume that an enzyme with RNase activity acts upstream of lysosomal RNA 
recognition. 
In this study we exploit the human myeloid BLaER1 cells to investigate the exact substrate 
specificity and activation mechanism of TLR8. Using this cell line, we aimed to identify 
potential enzymes acting upstream of the receptor, by systematically knocking out proteins 
with RNase activity located in either the endolysosomal compartment or the extracellular 
space, using CRISPR/Cas9 mediated genome editing. Subsequently, a minimal motif for TLR8 






3 Materials and Methods 
 Material 
3.1.1 Antibodies 
Antibody Source Identifier 
Anti-b-Actin-HRP-coupled Santa Cruz Cat#sc-47778 HRP 
Direct-Blot HRP anti-FLAG tag  BioLegend Cat#637311 
Anti-RNase T2 Sigma-Aldrich Cat#HPA029013 
Anti-rabbit IgG HRP linked Cell Signaling 
Technology 
Cat#7074 




3.1.2 Bacterial strains 
Strain Source Identifier 
S. aureus subsp. aureus ATCC ATCC 6538 
 
3.1.3 Chemicals 
Chemicals and Reagents Source Identifier 
Agilent RNA 6000 Nano Kit Agilent Cat#5067-1511 
Ammonium persulfate Sigma-Aldrich Cat#A3678 
Blood agar plate OXOID Cat#PB5039A 
Doxycycline hyclate Sigma-Aldrich Cat#D9891 
EDTA (0.5M) Thermo Fisher Cat#15575020 
GeneJuice® Transfection Reagent Merck Chemicals 
GmbH 
Cat#70967 
Gentamicin Thermo Fisher Cat#15750060 
HisTrap™ GE Healthcare Cat#17-5247-01 
ISOGRO®-15N Powder-Growth Medium Sigma-Aldrich Cat#606871 
Lipofectamine 2000 Transfection Reagent Thermo Fisher 
Scientific 
Cat#11668019 
LPS-EB Ultrapure InvivoGen Cat#tlrl-3pelps 
nitrocellulose membrane (0.45µm) GE Healthcare Cat#10600002 
Pam3CSK4 InvivoGen Cat#tlrl-pms 





Phenol/Chloroform/Isoamyl alcohol Roth Cat#A156.3 
Phorbol 12-myristate 13-acetate (PMA) Enzo Life Sciences Cat#BML-PE160-0005 
poly-L-arginine  Sigma-Aldrich Cat#P7762  
Recombinant Human IL-3 MPI of Biochemistry, 
Munich 
N/A 
Recombinant Human IFN-𝛾 PeproTech Cat#300-02 
Recombinant Human M-CSF MPI of Biochemistry, 
Munich 
N/A 
R848 InvivoGen Cat# tlrl-r848 
SequaGel Concentrate national diagnostics Cat#EC8301L 
SequaGel Buffer national diagnostics Cat#EC835200ML 
SequaGel Diluent national diagnostics Cat# EC8401L 
Superdex-200 16/600 GE Healthcare Cat#28989335 
SYBR Gold Nucleic Acid Gel Stain Thermo Fisher 
Scientific 
Cat#S11494 
TL8-506 InvivoGen Cat# tlrl-tl8506 
TEMED Roth Cat#2367.3 
UltraPure 0.5M EDTA, pH 8.0 Thermo Fisher 
Scientific 
Cat#15575020 
ß-Estradiol Sigma-Aldrich Cat#E8875-250MG 
 
3.1.4 Critical commercial assays 
Kit Source Identifier 
Human IL-6 ELISA Set BD Biosciences Cat#555220 
 
3.1.5 Cell lines 
Cell Lines Source Identifier 
BLaER1 human b-cell to monocyte trans-differentiation cell 
line 
(Rapino et al., 2013) N/A 
HEK293T (Gaidt et al., 2017) N/A 














RNA40 (rGrCrCrCrGrUrCrUrGrUrUrGrUrGrUrGrArCrUrC) IDT N/A 
P20 (rUrUrGrArArGrGrArCrArUrGrUrCrCrUrUrCrArA) IDT N/A 






















rArArArGrGrArArA IDT N/A 
rArArArGrArArArA IDT N/A 
rArArArGrUrArArA IDT N/A 
rArArArGrCrArArA IDT N/A 
rArArArArGrArArA IDT N/A 
rArArArArArArArA IDT N/A 
rArArArArUrArArA IDT N/A 
rArArArArCrArArA IDT N/A 
rArArArUrGrArArA IDT N/A 
rArArArUrArArArA IDT N/A 
rArArArUrUrArArA IDT N/A 
rArArArUrCrArArA IDT N/A 
rArArArCrGrArArA IDT N/A 
rArArArCrArArArA IDT N/A 
rArArArCrUrArArA IDT N/A 




dAdCdAdCdAdCdAdCdAdCdAdCdAdCdAdC IDT N/A 









dAdCdAdCdAdCdAdCdAdCdAdCdAdC*rU*rU IDT N/A 
 
3.1.7 Plasmids 
Plasmids Source Identifier 
pcDNA3.1_RNase T2_PreScission_6xHis This study N/A 
pLI_hu_RNase T2_FLAG_Puro This study N/A 
pLI_mScarlet _Puro This study N/A 
CMV-mCherry-Cas9 (Schmid-Burgk et al., 
2014) 
N/A 
pLK0.1-gRNA-CMV-GFP (Schmid-Burgk et al., 
2014) 
N/A 




3.1.8 Software and algorithms 
Plasmids Source Identifier 
GraphPad Prism 8 GraphPad N/A 
Outknocker (Schmid-Burgk et al., 
2014) 
N/A 
Adobe Illustrator v21.0.0 Adobe N/A 
 
3.1.9 Primer 
Name Sequence Used for 
TLR7_Fwd ACACTCTTTCCCTACACGACGctcttccgatctAATGTCACAGCCGTCCCTAC MiSeq 
TLR7_Rev TGACTGGAGTTCAGACGTGTGctcttccgatctAACTTTTAATTCTGTCAGCGCATC MiSeq 
TLR8_Fwd ACACTCTTTCCCTACACGACGctcttccgatctAATGCTGACCTGCATTTTCC MiSeq 
TLR8_Rev TGACTGGAGTTCAGACGTGTGctcttccgatctATTTTGCAGCCCTTGAAATG MiSeq 
RNaseT2_Fwd ACACTCTTTCCCTACACGACGctcttccgatctTGCAGTACCTGTATCTCGTTGG MiSeq 
RNaseT2_Rev TGACTGGAGTTCAGACGTGTGctcttccgatctCAAGCTAGGGTTCCCAGTCA MiSeq 
RNase1_Fwd ACACTCTTTCCCTACACGACGctcttccgatctTCCTGATACTGCTGGTGCTG MiSeq 
RNase1_Rev TGACTGGAGTTCAGACGTGTGctcttccgatctTCTTGCAGGTGACCTTTTCC MiSeq 





RNase2_Rev TGACTGGAGTTCAGACGTGTGctcttccgatctTGGTGACAATTTTTGCGAGT MiSeq 
RNase6_Fwd ACACTCTTTCCCTACACGACGctcttccgatctTGGTGCTATGCTTTCCTCTTC MiSeq 






















CMV-F CGCAAATGGGCGGTAGGCGTG Sequencing 
U6_Fwd GAGGGCCTATTTCCCATGATTCCT Sequencing 
LICsgRNA_rev P-AACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
 
3.1.10 sgRNA 
The sgRNAs were designed using a web tool called CHOPCHOP. The oligonucleotide for LIC 
cloning is composed of 5’-GGAAAGGACGAAACACCG-3’ followed by the target sequence 
without the PAM and without the first nucleotide, followed by 5’-
GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG-3’. 














3.1.11 Media and buffers 
Buffer Ingrediencies 
Cell culture medium 500 ml RPMI or DMEM 
10% heat inactivated FCS (v/v) 
Sodium pyruvate (1 mM) 
100 U/ml Penicillin-Streptomycin  
Direct lysis buffer 0.2 mg/ml Proteinase K 
1 mM CaCl2 
3 mM MgCl2 
1 mM EDTA 
1 % Triton X-100 
10 mM Tris pH 7.5 
DISC 30 mM Tris-HCl 
150 mM NaCl 
10 % Glycerol (v/v) 
1 % Triton-X-100 (v/v) 
pH 7.5 
LB agar 20 g LB 
15 g Agar 
1 l H2O 
Autoclave before usage 
LB medium 20 g LB 
1 l H2O 
Autoclave before usage 
Miniprep buffer P1 50 mM Tris pH 8.0 
10 mM EDTA 
100 μg/ml RNase A 
Miniprep buffer P2 200 mM NaOH 
1 % SDS 
Miniprep buffer N3 4.2 M guanidine hydrochloride 
0.9 M Potassium acetate 
pH 4.8 
Miniprep buffer PE 10 mM Tris pH 7.5 
80 % ethanol 
TAE buffer 40 mM Tris pH 8.0 
20 mM acetic acid 
1 mM EDTA 
10x TBE buffer 1 M Tris 
1 M boric acid 







TBS-T buffer 137 mM NaCl 
2.7 mM KCKl 
19 mM Tris 
0.05 % Tween 20 
pH 7.4 
TFBI 100 mM RbCl 
50 mM MnCl2 
30 mM KAc 
10 mM CaCl2 
15 % Glycerol 
pH 5.8 
TFBII 10 mM MOPS 
10 mM RbCl 
75 mM CaCl2 
15 % Glycerol 
pH 6.8 
6x Lämmli buffer 60 mM Tris pH 6.8 
9,3 % DTT (w/v) 
12 % SDS (w/v) 
47 % glycerol (v/v) 
0,06 % bromophenol blue (w/v) 
 
3.1.12 Laboratory equipment 
Device Supplier 
Absorbance readers TECAN/ Epoch 
Biomek FX Robot Beckmann Coulter 
Chemidoc imaging system Bio-Rad 
Fusion Fx device Vilber 
Gene Pulser Xcell Bio-Rad 
Nanodrop Peqlab 
PCR cycler Bio-Rad 
Sony sorter SH800Z Sony 
Thermoshaker Eppendorf 







 Molecular biology methods 
3.2.1 Generation of chemically competent E. coli 
200 ml LB medium was inoculated with E. coli (DH5α) and incubated over night at 37 °C. The 
next day 200 ml of LB medium was inoculated 1:100 with the overnight culture and grown for 
3 h. Bacteria were incubated on ice for 15 min before they were centrifuged for 10 min at 
2700 g at 4 °C. The pellet was resuspended in 30 ml chilled TFBI buffer and incubated on ice 
for 10 min. Cells were centrifuged at 600 g in 4 °C for 10 min. After removing the supernatant 
cells were gently resuspended in 4 ml chilled TFBII and aliquoted (40 µl). After snap freezing 
in liquid nitrogen competent bacteria were stored at -80 °C. 
3.2.2 Restriction enzyme cloning 
To obtain the needed DNA plasmids, genes were amplified from human cDNA by PCR. The 
needed restriction sites were added by overhanging primers in a second PCR step. The insert 
as well as the vector were digested with the respective restriction enzymes (Thermo Scientific, 
FastDigest) according to supplier’s protocol. The plasmid was furthermore incubated with Fast 
AP (Thermo Scientific, #EF0651) for 15 min, to remove the 5’-phosphate and prevent re-
ligation of the vector. The digested DNA fragments were purified by agarose gel purification 
(QIAquick Gel Extraction Kit) and ligated with T4 ligase (Thermo Scientific, #EL0011) in a 
molecular ratio of 1:3 (vector:insert). The ligation was also performed according to the 
supplier’s protocol. The ligation mixture was transformed into E. coli. 
3.2.3 Generation of gRNA-plasmids by ligation independent cloning (LIC) 
If the needed sgRNA could not be found in the sgRNA library (Schmidt et al., 2015), a new 
sgRNA plasmid was generated by ligation independent cloning (LIC). To design an early 
targeting sgRNA, present in all annotated splice variants, the web based tool CHOPCHOP was 
used (Montague et al., 2014). The according DNA with overhangs complementary to the 
vector was ordered and cloned into an expression plasmid: 
2 µg empty expression vector was digested with the FastDigest enzymes ApaI and SpeI and 
purified by agarose gel extraction. The essential overhangs were generated by the 3’-5’ 







10 µl 10x NEB2 buffer 
10 µl Vector 70ng/µl 
1 µl BSA 10mg/ml 
1 µl dTTP 100 mM 
74.66 µl H2O 
3.33 µl T4 DNA polymerase 3 U/µl 
The reaction mixture was incubated for 5 min at 27 °C, put on ice and heat inactivated for 
20 min at 75 °C. The chewed vector was mixed with the universal reverse binding 
oligonucleotide LICsgRNA_rev (PAGE purified, IDT): 
20 µl 10x NEB2-puffer 
10 µl Chewed vector 
0.5 µl LICsgRNA_rev 100µM 
69.5 µl H2O 
2.5 µl master mix was added to 2.5 µl of sgRNA oligonucleotide (0,25 µM) and annealed 
according to the following protocol: 
70 °C 1 min 
65 °C 1min 
60 °C 30 sec 
55 °C 2.5 min 
25 °C ∞ 
Afterwards the mixture was transformed into chemically competent E. coli. 
3.2.4 E. coli transformation 
Chemically competent E. coli were thawed on ice before adding the plasmid DNA and 
incubated 15 min on ice. Cells were heat shocked at 42 °C for 45 s and put back on ice for 
2 min. After adding 250 µl LB medium bacteria were shaken for 30 min at 37 °C. They were 
plated on an agar plate with appropriate antibiotics. 
3.2.5 Plasmid isolation from E. coli 
Plasmids were isolated according to the protocol of the QIAprep Spin Miniprep Kit (Qiagen). 
The buffers for the purification are self-made. For higher yield and purification, the Midi and 
Maxi Kits from Invitrogen (#K210014, #K210006) were used. 





3.2.6 Sanger sequencing 
Sanger sequencing was performed by Eurofins (TubeSeq service). 
3.2.7 PCR 
For all performed PCRs Phusion High-Fidelity DNA Polymerase (Thermo Scientific, #F530L) was 
used according to the manufacture’s protocol. 
3.2.8 Agarose gel electrophoresis 
To analyze the size of DNA fragments a 1 % (w/v) agarose gel was cast. For visualization ROTI 
GelStain (#3865.2) was used in a final concentration of 0.005 %. Samples were mixed with 
loading dye and run at 120 V for 30-40 min. 
3.2.9 Bioanalyzer 
S. aureus total RNA analysis was performed using the Agilent Bioanalyzer device. The RNA 
6000 Nano kit (#5067-1511) was used according to the supplier’s protocol. 
3.2.10 Urea gel 
Urea Gels were cast using SequaGel Concentrate, SequaGel Diluent and SequaGel Buffer 
according to the supplier’s protocol. Samples were loaded using 2x RNA gel loading dye 
(Thermo Fisher #R0641) and the gel was run at 250 V for 70 min in TBE buffer. It was stained 
with SYBR Gold and imaged using a UV table. 
3.2.11 RNA precipitation 
RNA was purified by sodium acetate precipitation. Samples were mixed with a 3 M sodium 
acetate solution, resulting in a final concentration of 0.3 M. 4 volumes 100 % EtOH were added 
to the samples and incubated for 1 h at -20 °C. After centrifugation for 30 min at full speed 







 Cell culture methods 
3.3.1 Cell lines 
BLaER1: a subclone of human B cell Lymphoma expressing the transdifferentiation construct 
CEBPa-ER-GFP. 
THP-1 (ATCC® TIB202TM): monocytic cell line obtained from human leukemia patient. 
HEK 293T (ATCC® CRL-3216TM): HEK 293T human embryonic kidney cells stably expressing 
SV40 large T antigen. 
3.3.2 Cell culture 
BLaER1 (Rapino et al., 2013) and THP-1 cells were cultured in RPMI medium whereas HEK293T 
were grown in DMEM. BLaER1 cells were trans-differentiated for 5-6 days with medium 
containing 10 ng/ml IL-3, 10 ng/ml CSF-1 (M-CSF) (MPI of Biochemistry, Munich) and 100 nM 
ß-estradiol. All experiments were carried out in a 96-well format with 80,000 cells/well. In this 
study BLaER1 cells with a CASP4-/- genetic background were used. Furthermore, we noticed 
the infection of this cell line by SMRV (Squirrel monkey retrovirus). Further experiments 
confirmed the integration of viral DNA into the BLaER1 genome. However, testing early 
passages of BLaER1 cells confirmed that the parental cell line was already infected with SMRV. 
Of note, the extensive testing of BLaER1 cells also in comparison with other human myeloid 
cells did not give any indication that the SMRV infection would influence the experimental 
outcome of the cell line. 
THP-1 cells were differentiated in 10 cm dishes using RPMI medium supplemented with 
100 ng/ml PMA for 16 h. Cells were washed with PBS twice, detached and seeded into 96-well 
plate (80,000 cells/well). After a resting phase of 3 days cells were stimulated with IFN-g for 
6 h. 
3.3.3 Cell stimulation 
BLaER1 cells were stimulated with all different kind of RNA oligonucleotides which either had 
a phosphorothioate backbone stabilization or a normal phosphodiester backbone. For cellular 
delivery the RNA was complexed with poly-L-arginine in a 1:1 ratio (Ablasser et al., 2009). If 
not otherwise indicated, stimulation with RNA 40 was performed with 0.6 µg/well. For all 
condition involving ex cellulo digestion of any ONs, 1.2 µg was transfected to account for 
cleavage activity of RNaseT2. The transfection was performed as follows: RNA and Poly-L-





Afterwards the two components were mixed and incubated for 20 min at room temperature. 
After exchanging the medium (100 µl/well), 50 µl transfection mix was added. The 
transfection of RNA with Lipofectamine 2000 (LF) was performed according to the supplier’s 
protocol. As control, cells were stimulated with either 200 ng/ml LPS, 1 µg/ml R848 or 
100 ng/ml TL8-506. Stimulations were carried out at 37 °C for 14-16 h. 
To stimulate cells with RNA degradation products, 1-2 µg of ONs was digested with either 
RNaseT2 (made in this study) or RNase A (Invitrogen, Maxiprep Kit, #K210017). The digest was 
performed for 20 min at 30 °C in a total volume of 10 µl (IDTE buffer pH 8). After digest, the 
RNA fragments were transfected using poly-L-arginine and cells were stimulated for 14-16 h 
at 37 °C. 
For bacterial infections with S. aureus subsp. aureus (ATCCâ 6538Ô), bacteria were grown 
overnight on blood agar plate at 37 °C. The next day bacteria were scraped and resuspended 
in PBS. After centrifugation for 5 min at 4000 g cells were resuspended in RPMI medium 
without antibiotics. 100µl (per 96-well) of bacteria containing medium (with the indicated 
MOI) was added onto cells and incubated for 1 h at 37 °C. Afterwards the medium was topped 
up with 50 µl RPMI containing gentamicin, resulting in a final concentration of 50 µg/ml. 
Stimulation was carried out for another 14 h at 37 °C. Stimulation with 15N labeled S. aureus 
was performed according to the same protocol. 
Differentiated THP-1 cells were stimulated with 1.2 µg RNA40, complexed with poly-L-arginine 
in a 1:1 ratio. RNA and Poly-L-arginine were separately incubated in Opti-MEM (Gibcoâ) (25 
µl per 96-well each). After 5 min the two components were mixed and incubated for 20 min 
at room temperature. After exchanging the medium (100 µl/well), 50 µl transfection mix were 
added on top. As control, THP-1 cells were stimulated with either 0,33 µg/ml Pam3CSK4, 2 
µg/ml R848 or 200 ng/ml TL8-506. All stimulations were carried out for 14-16 h at 37 °C. 
 Cell biology methods 
3.4.1 15N-labeling of S. aureus 
S. aureus were labeled as follows: ISOGRO-15N powder was purchased and dissolved in water 
to a final concentration of 0.5g/50ml and supplemented with K2HPO4 (10 mM), KH2PO4 (10 
mM), MgSO4 (10 mM) and CaCl2 (0,1 mM). 5 ml medium were inoculated with S. aureus subsp. 
aureus (ATCCâ 6538Ô), grown for 16 h and harvested by centrifugation (8min at 5000 g). 





3.4.2 Lentiviral expression and transduction of BLaER1 cells 
To generate cell lines expressing the gene of interest in an inducible fashion, the third-
generation lentiviral vector system was used. This system is extremely safe as the needed 
proteins for viral particle formation are separated on four plasmids: pLI_GeneOfInterest 
(transfer plasmid), pMDLg/pRRE and pRSV-rev (packaging plasmids) and pCMV-VSV-G 
(envelope plasmid). The DNA (1 µg transfer plasmid, 1.5 µg pMDLg/pRRE, 0.5 µg pRSV-rev and 
1 µg pCMV-VSV-G in 200 µl opti-MEM) and PEI Max mix (10.6 µl PEI Max in 200 µl Opti-MEM) 
were prepared separately and incubated for 5 min at room temperature. Afterwards they 
were mixed and incubated another 25 min at room temperature. 300 µl transfection mix was 
added to 1 ml cell suspension containing 2x106 HEK 293T cells and put into a 6-well. After 2 h 
the medium was topped up with FCS containing DMEM medium resulting in a final FCS 
concentration of 30 %. After 16 h the supernatant was harvested, centrifuged for 5 min at 
500 g and filtered (0.45 µm). 750 µl of virus supernatant were mixed with 750 µl cell 
suspension containing 2x106 BLaER1 cells and put in a 6-well plate. After 24 h the medium was 
exchanged with fresh RPMI and cells were transferred to a T25 flask. For selection of 
transduced cells, puromycin (1.25 µg/ml) was added to the medium. Selection pressure was 
kept up for one week prior to analysis of surviving cells. 
3.4.3 RNA-seq 
Undifferentiated as well as differentiated BLaER1 cells were lysed in Trizol (2x106/1ml) and 
total RNA was purified using the Zymo Direct-zol RNA Miniprep. Total RNA was used to 
generate stranded RNA sequencing libraries using the Encore Complete RNA-Seq™ library 
system of NuGEN. The libraries were sequenced on an Illumina HiSeq1500 device. The reads 
were aligned to the human reference genome (Ensemble genome version 91) using STAR 
(Dobin et al., 2013). The transcripts were quantified using RSEM (Li and Dewey, 2011) and 
TPM (Transcripts Per Kilobase Million) values are shown as normalized gene expression. All 
RNA-seq datasets were generated in this study, except for THP-1 data which are derived from 
a public database (GEO, GSE 62171). 
 Mass spectrometry 
All mass spectrometry measurements (LC/MS and MALDI) were performed by Mirko Wagner 






For LC/MS analysis 3x106 BLaER1 cells were lysed in 750 µl of a 1:1 mixture of water and 
acetonitrile for 10 min. The samples were centrifuged for 10 min at 21,000 g and the 
supernatant was flash frozen. After freeze-drying, the samples were re-dissolved in 300 µl 
miliQ water. The samples were centrifuged for 30 min at 21,000 g in 4 °C and the supernatant 
transferred to a new tube to solely obtain the soluble cell pool. Before mass spectrometry 
measurement, 10 µl of a 0.3 µM 2-(D3-methyl)guanosine (D3-m2G; 3 pmol; synthesized in the 
Carell group (Globisch et al., 2011)) solution (dissolved in milliQ-water) was added to 90 µl of 
the sample serving as internal standard. The mixture was vortexed for 60 s and analyzed by 
LC-HESI-MS using a Dionex Ultimate 3000 HPLC system coupled to a Thermo Fisher LTQ 
Orbitrap XL mass spectrometer. For comparability, the injection volume was constantly kept 
at 90 µl (out of 300 µl total volume) per technical replicate. Nucleoside / nucleotide 
separation was performed using an Interchim Uptisphere 120-3HDO C18 column with a 
constant temperature of 30 °C. For elution the buffers A (2 mM NH4HCOO in H2O; pH 5.5) and 
B (2 mM NH4HCOO in H2O/MeCN 20/80 v/v; pH 5.5) were used at a constant flow rate of 
0.15 ml/min. The two buffers were gradually mixed over time: 0→10 min, 0% B; 10→15 min, 
0→0.1% B; 15→50 min, 0.1→5% B; 50→90 min, 5→100% B. The chromatogram was recorded 
at 260 nm with a Dionex Ultimate 3000 Diode Array Detector. The eluent was directly injected 
into the mass spectrometer without splitting. Samples were measured in the positive polarity 
mode scanning the full range between m/z 225-2000 with a resolution of 60,000. The mass 
spectrometer was calibrated using a freshly mixed inosine (5µM) solution in buffer A. The 
parameters were set as follows: capillary temperature 275.00 °C; source voltage 4.80 kV; 
capillary voltage 0.00 V; tube lens voltage 45.00 V. The areas under the curve were integrated 
after the ion chromatograms of the compounds of interest were extracted from the total ion 
current (TIC) chromatogram. To make the samples more comparable, the integrals of the 
found molecules were divided by integral of the internal standard D3-m2G. Importantly, the 
sulfur atom in RNA40S derived fragments led to diastereomeric configurations, generating 
several peaks for each molecule in the liquid chromatography. To this end, we only used the 
most abundant peak for quantification. 
In samples stimulated with 15N-labeled S. aureus, the fully labeled fragments were by far more 
abundant than the respective fragment with less 15N-atoms. Therefore, only the fully labeled 
fragments were considered for MS-based quantifications. 
To determine the substrate specificity of RNase T2 basically the same HPLC-ESI-MS setup was 
used (a Dionex Ultimate 3000 HPLC system coupled to a Thermo Fisher LTQ Orbitrap XL mass 





0.2 ml/min. Furthermore, the gradient was altered: 0→5 min, 0% B; 5→20 min, 0→5% B; 
20→30 min, 5→100% B. The chromatogram was also recorded at 260 nm using a Dionex 
Ultimate 3000 Diode Array Detector. Whereas the MS analysis was critical to identify the 
found fragments, the UV trace was used to calculate how efficient the RNA molecule was 
cleaved. Therefore, the sum of the integrals of all cleaved fragments was divided by the 
integrals of all found fragments (including the full length). As the oligonucleotides were 
bearing multiple charges the MS full-scan range of m/z 225-2000 was used. 
3.5.2 MALDI 
1200 ng of the respective RNA ON was digested by adding either RNase T2 (5-50 pg/µl) or 
RNase A (5-50 pg/µl) for 20 min at 37°C. The total reaction volume was 10 µl, which was filled 
up to 300µl after digestion using water. To inactivate the enzyme and for further purification 
the samples were mixed with Roti®-Phenol/Chloroform/Isoamyl alcohol in a 1:1 ratio and flash 
frozen. If not otherwise indicated, all following steps were performed at room temperature. 
The thawed samples were centrifuged for 3 min at 21,000 g and the aqueous (upper) phase 
was transferred to a new tube. To remove the remaining phenol, the samples were washed 
twice with chloroform as follows: The aqueous phase was mixed with equal amounts of 
chloroform and vortexed for 30 s. After centrifugation at 21,000 g for 3 min the aqueous 
phase was again transferred to a fresh tube. Subsequent of the two washing steps the samples 
were freeze-dried. After re-dissolving them in 60 µl milliQ-water, they were centrifuged for 
30 min at 21,000 g and 4 °C. The supernatant was taken and analyzed by HPLC (Waters e2695 
Separations Module) using an injection volume of 50 µl. For separation an EC 250/4 Nucleodur 
100-3 C18ec column was used, which was constantly kept at room temperature. The 
chromatogram was recorded at 260 nm using a Waters 2489 UV/Visible Detector. For elution 
buffer C (0.1 M NEt3/HOAc in H2O) and buffer D (0.1 M NEt3/HOAc in H2O/MeCN 20/80 v/v) 
were used at a constant flowrate of 0.5 ml/min. The following gradient was used: 0→45 min, 
0→25% D; 45→47 min, 25→100% D. The fractions were freeze-dried and re-dissolved in 10 µl 
milliQ-water. The samples were desalted for 3 h using a MF-Millipore Membrane Filter with a 
pore size of 0.025 µm. Subsequent a MALDI-MS analysis was performed using an autoflex II 
system (Bruker Daltonics) in the negative polarity mode. Therefore, 1.5 µl of HPA-matrix 
(3-hydroxypicolinic acid) was used per 1.5 µl desalted sample. All MALDI experiments were 





 Biochemical methods 
3.6.1 Protein purification 
The human RNase T2 protein (residues 1-256) was amplified from cDNA derived from BLaER1 
cells. It was either cloned in a pcDNA3.1 vector or the piggyBAC vector system (Li et al., 2013), 
using conventional enzyme cloning. Both systems were used for protein purification and 
yielded RNase T2 with over 90% purity, which was determined by Coomassie stanning and 
mass spectrometry. Protein activity was comparable between both approaches. 
Using the pcDNA3.1 vector system the plasmid (pcDNA3.1_RNase T2_PreScission_6xHis) was 
transfected into HEK293T cells. For protein purification the supernatant of six 10 cm dishes 
was harvested and centrifuged for 5 min at 500 g and 4 °C. The supernatant was filtered and 
loaded onto a 1 ml HisTrap™. The column was subsequently washed using 20 column volumes 
(CV) of wash buffer (20 mM K2HPO4, pH 7.5, 0.5 M NaCl, 20 mM Imidazole). The protein was 
eluted by using a gradient of Buffer A (wash buffer) and buffer B (1 M imidazole) over 10 CV. 
RNase T2 containing fractions were subsequently purified by size exclusion chromatography 
(SEC) using a Superdex-200 16/600 in SEC buffer (200 mM NaAc pH 6.0, 50 mM NaCl). The 
protein was concentrated and flash frozen for storage at -80 °C. 
The piggyBac_RNase T2_PreScission_6xHis plasmid was used to generate stable HEK293T/17 
SF cells. Stable cells were grown in 1 l medium to a density of 1 x 106 cells/ml. For selection 
cells were treated with Doxycycline (1 ug/ml). Supernatant was harvested after 7 days and 
concentrated using a Sartocon Slice 200, 10 kDa MW cutoff (Sartorius) in PBS. The protein was 
subjected to size exclusion chromatography in SEC buffer (200 mM NaAc, 50 mM NaCl, pH 6.0) 
using a HiLoad 26/60 Superdex 200 (GE healthcare). Fractions containing RNase T2 were 
concentrated using a 10 kDa cut-off, Amino Ultra 15 concentrator (Amicon), to a concentration 
of 11 mg/ml and flash frozen in liquid nitrogen. 
3.6.2 Immunoblotting 
For western blots of whole cell lysate, 1x106 cells were stimulated in a 96-well format for 14 h. 
Cells were detached from the dish using PBS-EDTA (Invitrogen, #15575020, 2 mM), pooled 
and centrifuged for 5 min at 500 g. The supernatant was removed, and cells were lysed in DISC 
buffer for 10 min on ice. To get rid of the nuclei, cells were centrifuged for 10 min at 16,000 g. 
The supernatant was mixed with 6x Lämmli buffer and denatured for 5 min at 85 °C. The 
proteins were separated using a precast tris-glycine denaturing SDS-PAGE (Invitrogen, Novex 
Tris-Glycine Gels) and transferred onto a 0.45 µm nitrocellulose membrane by wet blotting. 





overnight. The membrane was washed 3 times with TBS-T for 5 min and incubated with the 
corresponding secondary HRP-coupled antibody for 1 h. After another 3 washes 
chemiluminescence was measured using a CCD-camera and respective images were contrast-
enhanced in a linear fashion. The antibodies were diluted as follows: 
Anti-RNase T2 1:500 
Anti-TLR8 1:1000 
Anti-FLAG HRP 1:1000 
Anti-b-Actin-HRP 1:1000 
Anti-rabbit IgG HRP Antibody 1:1000 
 CRISPR/Cas9 mediated knockout-cell line generation 
Knockouts were generated using the CRISPR/Cas9 system throughout the whole manuscript. 
BLaER1 KO generation was performed according to a published protocol (Schmid-Burgk et al., 
2014). Therefore, sgRNAs (18- or 20-mer) targeting an early coding exon were designed and 
cloned into an expression plasmid. BLaER1 cells were electroporated with the plasmid carrying 
the respective sgRNA as well as Cas9-T2A-BFP. BLaER1 cells were sorted for high BFP 
expression and serially diluted to obtain monoclones. 
As THP-1 cells could, due to their strong immune response upon DNA recognition, not be 
electroporated with plasmid DNA, ribonucleoprotein (RNP) complexes were delivered by 
nucleofection (Lonza). As this led to very efficient KO generation, cells were directly subjected 
to serial dilution. All genotypes (BLaER1 and THP-1) were subsequently analyzed by deep 
sequencing (MiSeq). 
3.7.1 Electroporation of BLaER1 cells 
Fresh BLaER1 cells were adjusted to 2.5x105 cells /ml 24 h prior to electroporation. Cells were 
counted and adjusted to 1x107 cells/ml in Opti-MEM. 250 µl cell suspension was mixed with a 
total of 5 µg DNA. The mixture was incubated for 15 min at room temperature and transferred 
to an electroporation cuvette. The electroporation was performed with the Gene Pulser Xcell 
Electroporation system from BIO-RAD using the following settings: 265 V, 975 µF and 720 Ω. 
Cells were quickly transferred into 2 ml prewarmed RPMI medium and incubated in a 6-well 





3.7.2 FACS sorting of BLaER1 cells 
24 h to 48 h after electroporation cells were spun down for 5 min at 500 g, resuspended in 
500 µl medium and put through a cell strainer. To sort the cells either the SONY SH800Z or the 
BD FACS Melody sorting device was used. BFP positive BLaER1 cells were sorted and used for 
serial dilution. 
3.7.3 Nucleofection of THP-1 cells 
As THP-1 cells were generated using RNPs and could therefore not be sorted to enrich for 
positive cells, each gene was targeted by two sgRNAs located in close proximity to increase 
the KO efficiency. First, the CRISPR RNA (crRNA) and the Trans-activating crRNA (tracrRNA) 
had to be annealed in a 1:1 ratio. The tracrRNA is identical for all genes and is essential for 
binding Cas9. The crRNA on the other hand provides specificity and guides the Cas9 protein to 
the target gene. The annealing was done as follows: 











Afterwards, the nucleofection mix was prepared and incubated for 10 min at room 
temperature to allow RNP formation. It was prepared using the SG Cell Line 96-well 
NucleofectorTM Kit: 
gRNA mix 5 µl 
IDT Cas9 (c=62 µmol/l) 1.3 µl 
Supplement 4.5 µl 
NucleofectorTM solution 14.2 µl 
Next, 5x105 THP-1 cells were centrifuged for 5 min at 500 g washed with PBS and resuspended 
in 25 µl nucleofection mix. The mixture was transferred into a cuvette and nucleofected using 





plate containing 200 µl prewarmed RPMI and incubated for 24 h at 37 °C. The next day cells 
were expanded into a 48-well and incubated another 24 h. 
3.7.4 Monoclone generation by serial dilution 
To obtain monoclones, cells were serially diluted. To this end, sorted (BLaER1) or unsorted 
(THP-1) cells were diluted and plated in a 96-well format. For BLaER1 cells three plates of each 
4, 2 and 1 cell/well were plated. For THP-1 on the other hand six plates with only 1 cell/well 
were seeded. After 3-4 weeks grown colonies were re-formatted onto a new 96-well plate 
using a Beckmann Coulter Biomek FK robot. The genotype of picked cells was subsequently 
analyzed by deep sequencing. 
3.7.5 K.O. Identification by deep sequencing 
To analyze the genotype of generated monoclones a deep sequencing approach was 
performed using the illumina MiSeq (MiSeq reagent kit v2) device. Therefore, cells were lysed 
for 10 min at 65 °C using direct lysis buffer, followed by a heat inactivation step for 15 min at 
95 °C. As it is essential for sequencing to label each amplicon with a unique barcode set, a two-
step PCR approach was used. The first PCR specifically amplifies the gene of interest and 
generates an approximately 250 bp long DNA fragment located at the target site. Of note, it is 
essential for further analysis, that the targeted region is not within the first or last 50 bp of 
the amplicon. Furthermore, the primers carry overhanging adapter sequences, which serve as 
binding site for the second PCR primers rendering their sequence independent of the target 
sequence. The second PCR is essential to add a unique set of barcodes as well as the Illumina 
sequencing adapters to the PCR product. Therefore, 16 different forward and 24 different 
reverse barcode primers were mixed to obtain 384 unique primer combinations. All PCR 
products were then pooled subjected to agarose gel purification, precipitated and quantified. 
Both PCRs were performed using Phusion polymerase according to the supplier’s protocol: 
95 °C 3 min 
95 °C 30 sec 
63 °C 30 sec 
72 °C 30 sec 
72 °C 3 min 
4 °C ∞ 
Sequencing of the purified DNA was performed using an Illumina MiSeq device (MiSeq 
Reagent Kit v2, 300 Cycles, #MS-102-2002). Analysis of FastQ-files was done with help of the 






the reads according to the barcodes as well as the amplicon sequence of the target gene and 
thereby identifies possible insertions or deletions. Only clones with both allelic out-of-frame 
insertion/deletions were picked. If possible 3-6 clones of each genotype were picked and 
tested for phenotypes. 
 Quantification and statistical analysis 
If not otherwise indicated, statistical significance was determined by two-way ANOVA with 
Dunnett’s or Tukey’s correction for multiple testing using GraphPad Prism 8 (except for 
normalized LC/MS data): ****p ≤ 0.0001; *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, ns = not 
significant. If multiple comparisons are depicted with one comparison bar, the major tick of 
the comparison bar indicates the reference data to which the statements regarding the level 
of significance are made. LC/MS data was normalized by dividing the values of RNASET2-/- cells 
by the values of Ctrl cells. These values were then transformed into a Log2 scale and a Welch’s 
unequal variances t test was performed. Undetectable values were replaced with 1/10 of the 
lowest non-zero value of the corresponding dataset. The analysis was performed using R. 
 Data availability 
BLaER1 RNA-Seq data can be accessed at Gene Expression Omnibus (GEO: GSE138913) or at 







 TLR7 and TLR8 are functional TLRs in BLaER1 monocytes 
To study the activation mechanism of TLR8 we decided to exploit the BLaER1 cell system, 
which had already earlier been used to model human monocytes (Gaidt et al., 2017; Gaidt et 
al., 2016). This B-cell lymphoma cell line can be trans-differentiated into macrophage-like cells 
by adding a cytokines cocktail containing IL-3 and M-CSF as well as b-estradiol (Rapino et al., 
2013). In these cells the endolysosomal receptors TLR7 and TLR8, recognizing ssRNA, are 
upregulated upon trans-differentiation. The same is true for the LPS sensor TLR4 which was 
stimulated as control (Figure 4.1A). As prototypic TLR8 agonist we used the well-established 
RNA40 ligand, a 20-mer ssRNA oligonucleotide (ON) derived from HIV-1 genome (Heil et al., 
2004). In this study a modified version of RNA40 named RNA40S was used, which has 
Figure 4.1 Characterization of TLR7 and TLR8 in BLaER1 cells 
(A) Gene expression change of differentiated vs un- differentiated BLaER1 monocytes are shown as volcano plot 
with negative log10 p-values on the y-axis plotted against log10 changes in gene expression on the x-axis. 
Significantly upregulated genes are depicted in red whereas downregulated ones are shown in blue. Significance 
is defined by a p-value < 0.05 and absolute fold change > 2. The receptors TLR4, 7 and 8 are highlighted. (B and 
C) Differentiated BLaER1 cells of indicated genotype were stimulated with (B) TL8-506, R848 and LPS or (C) 
unstimulated, poly-L-arginine (pR) and transfected with RNA40S. Supernatants were harvested 14 h after 
stimulation and analyzed by ELISA. Data are depicted as mean + SEM of three independent experiments. 






phosphorothioate linked bases, instead of phosphodiester linkage. This protects it against 
degradation and increases its half-life compared to unmodified ONs. To deliver RNA40 
specifically into the endolysosomal compartment, the polycationic polypeptide poly-L-
arginine (pR) was used (Ablasser et al., 2009). As a proxy for TLR8 activation, the pro-
inflammatory cytokine IL-6 was measured by ELISA, which gets expressed as a result of NF-kB 
activation downstream of the receptor. Stimulation of BLaER1 cells with either TL8-506 (TLR8 
ligand), R848 (TLR7/8 ligand) or LPS (TLR4 Ligand) led to high IL-6 levels (Figure 4.1B). As 
expected, TL8-506 was TLR8 specific and IL-6 production was abolished in TLR8-/- cells. R848 
Figure 4.2 TLR7 and TLR8 are functional receptors in BLaER1 cells 
(A) BLaER1 cells of indicated genotype were transfected with Lipofectamine 2000 either with or without RNA40S. 
(B) TLR8 expression level in BLaER1 cells of indicated genotype was analyzed by immunoblotting. (C) Ctrl and 
TLR8-/- BLaER1 cells were stimulated with increasing amounts of RNA40S. (D) BLaER1 cells were stimulated with 
increasing amounts of RNA40O, LPS or were unstimulated. The unstimulated control shown in (A), (C) and (D) is 
the same as it is derived from the same experiment. (E) BLaER1 cells of indicated phenotype were stimulated with 
the indicated stimuli. P20 is a self-complementary RNA forming a hairpin structure, whereas P20-5M in only 
partially self-complementary and has single stranded stretches. All supernatants were harvested after 14 h and 
IL-6 was measured by ELSA. Data are depicted as mean + SEM of three (A, C and D) or four (E) independent 
experiments. Statistical significance was calculated using two-way ANOVA: ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; 





on the other hand can activate TLR7 as well as TLR8 and cytokine production was only blunted 
if both receptors were absent. Stimulation only with the transfection reagent (pR) itself did 
not lead to any IL-6 release. TLR4 activation by its ligand LPS resulted in robust IL-6 expression 
in all tested genotypes. RNA40S stimulation on the other hand, was completely TLR8 
dependent (Figure 4.1C), which could also be observed after Lipofectamine transfection albeit 
at much lower levels (Figure 4.2A). The absence of TLR8 on a protein level in the respective 
cells was confirmed by western blot (WB) (Figure 4.2B). Increasing amounts of RNA40S led to 
increased IL-6 release reaching a saturation at 600 ng (Figure 4.2C). Studying phosphodiester 
linked RNA40, from now on referred to as RNA40O, also led to dose dependent IL-6 release, 
albeit resulting in lower cytokine levels compared to RNA40S (Figure 4.2D). Similar results were 
obtained by stimulating with an unrelated phosphodiester linked RNA named P20-5M (Figure 
4.2E). Whereas control BLaER1 monocytes produced robust amounts of IL-6 in response to 
P20-5M, TLR8-/- cells were unresponsive. As already published, a self-complementary version 
of the ON (P20) was not able to stimulate TLR8 at all (Ablasser et al., 2009). These results 
indicate that a certain degree of ssRNA is needed for TLR8 activation. All in all, these data 
establish the BLaER1 cells system as a good model to investigate the RNA dependent 
activation mechanism of TLR8 in the human context. 
 RNase T2 deficient cells fail to respond to RNA oligonucleotides 
In 2015 the crystal structure of TLR8 was solved and reveled that the receptor has two distinct 
binding sites. The first binding site is occupied by a single nucleotide (uridine) whereas the 
second pocket can bind to small RNA fragments like di- or tri-nucleotides (Tanji et al., 2015). 
Furthermore, it is known, that DNase II is generating appropriate ligands for TLR9 by 
degradation, upstream of the receptor (Chan et al., 2015). Therefore, we hypothesized, that 
there must most likely be an enzyme with RNase activity upstream of TLR8 generating small 
RNA fragments needed for its activation. To address this question, we performed an RNA 
sequencing analysis of several cell lines. We focused on proteins, which according to their 
gene ontology (GO) terms are annotated as either lysosomal, extracellular space or 
ribonuclease activity (Figure 4.3A). Only the four RNases RNASE2, RNASE3, RNASE6 and 
RNASET2 matched all three conditions, however, as only RNASE2, RNASE6 and RNASET2 were 
highly expressed in differentiated BLaER1 cells as well as in primary human monocytes we 
initially focused on these three. Additionally, we included RNASE1 as it is highly expressed in 
differentiated BLaER1 monocytes (Figure 4.3A, right panel). Using the CRISPR/Cas9 system we 
generated RNASE1-/-, RNASE2-/-, RNASE6-/- and RNASET2-/- single KOs in BLaER1 cells and 
stimulated them with RNA40S. Studying the respective KO cell lines reveled a complete loss-












Figure 4.3 RNaseT2-/- cells do not produce IL-6 upon RNA40 stimulation 
(A) Venn diagram of proteins which are due to their Gene Ontology (GO) term annotated as “lysosomal”, 
“extracellular space” or “ribonuclease activity” (left panel). Heat map displaying gene expression of diverse 
RNases in different cell types (middle panel). Heat map of the same RNases with their corresponding GO terms 
(right panel) (B) Ctrl and RNASET2-/- BLaER1 cells were stimulated with RNA40S, TL8-506, R848 and LPS. (C-E) 
BLaER1 cells of indicated genotypes were either unstimulated or stimulated with RNA40S, TL8-506, R848 and LPS. 
Controls of RNASE1-/- and RNASE6-/- are indicial as they derive from the same experiment. Data are depicted as 
mean + SEM of three independent experiments. Statistical significance was calculated using two-way ANOVA: 





did not lead to decreased IL-6 levels (Figure 4.3C-E). Interestingly, knocking out RNase T2 only 
led to blunted IL-6 levels upon RNA40S stimulation, but not upon TL8-506, R848 or LPS 
treatment. This indicates that RNase T2 has no impact on TLR8 activation per se, rather it is 
functioning upstream of it. The RNASET2-/- phenotype in BLaER1 cells upon RNA40S stimulation 
Figure 4.4 RNASE T2 deficiency can be rescued by lentiviral transduction of RNASET2 
(A) Lentiviral delivery was used to reconstitute RNASET2-/- cells with either RNASET2 or mScarlet (control). Gene 
expression was induced by doxycycline (++, 1 µg/ml; +, 0.5 µg/ml). (B) Immunoblot corresponding to the 
stimulation experiment in (A). Unspecific bands are indicated by asterisk. (C) THP-1 cells were differentiated with 
PMA and stimulated with poly-L-arginine (pR), RNA40S, TL8-506, R848 or PAM3. (D) BLaER1 cells of indicated 
genotype were stimulated as shown. Data of Ctrl cells are identical to the ones in Figure 4.2E as they derive from 
the same experiment. All stimulations were carried out for 14 h prior to IL-6 measurement. Data are depicted as 
mean + SEM of three (A-C) or four (D) independent experiments. Statistical significance was calculated using two-





could, however, be rescued by lentiviral transduction of RNASET2 (Figure 4.4A). After 
doxycycline induction IL-6 levels could be increased in a dose dependent manner nearly 
reaching wild type (WT) levels. The lack of RNase T2 as well as its increasing amounts after 
doxycycline induction could also be visualized by western blotting (Figure 4.4B). Similar results 
were obtained in THP-1 cells, knocking out RNASET2 or TLR8 (Figure 4.4C). Whereas control 
THP-1 cells released robust amounts of IL-6 after RNA40S stimulation, it was significantly 
reduced in both RNASET2-/- and TLR8-/- cells. Finally, we also tested the self-complementary 
ON P20 as well as the partially single stranded ON P20-5M in BLaER1 KO cells, showing that 
stimulation with P20-5M is significantly dependent on RNase T2 (Figure 4.4D). These data 
indicate that RNase T2 is critically and non-redundantly required to render RNA strands 
agonistic upstream of TLR8. 
 RNase T2 cleaves RNA between purine bases and uridine 
The previous results led to the conclusion, that RNase T2 is likely to function upstream of TLR8 
generating ligands for either its first or second binding pocket by RNA degradation. To further 
investigate this theory, we generated recombinant RNase T2 enzyme for subsequent in vitro 
analysis. Degradation of RNA40S with increasing amounts of recombinant RNase T2 showed a 
very specific degradation pattern resulting in distinct fragments. Interestingly, the 
degradation products were substantially different from the ones obtained by digesting 
RNA40S with bovine pancreatic RNase A which is orthologous to human RNase 1 (Figures 4.5A 
and B). To investigate the exact composition of these in vitro digests, RNase T2 as well as 
RNase A degradation mixtures were analyzed by HLPC and MALDI-TOF (all mass spectrometry 
experiments were measured by Mirko Wagner) (Figure 4.5C). Of note, to identify the cleavage 
pattern we initially studied degradation of RNA40O, as the analysis of RNA40S by HPLC is 
drastically more difficult: the phosphorothioate backbone of RNA40S leads to numerous 
diastereomers which all behave unique during HPLC separation, resulting in less defined peaks 
of each product. HPLC analysis revealed at least nine distinct peaks of which eight could be 
assigned to the according masses by MALDI-TOF. In the next step we tried to match the found 
masses with the calculated masses of possible RNA40O degradation products. As RNA40 is not 
very complex in terms of sequence, especially short fragments tend to have very similar 
masses, making it significantly harder to analyze. To this end, we assigned the found peaks not 
only by mass, but also by the notion that found fragments must in the end add up to a full- 
length RNA40 molecule. This allowed us to unequivocally identify six fragments (all terminal 
ones) and two with high probability (Figure 4.5D). Interestingly, the found degradation 







Figure 4.5 In vitro digest of RNA40 by RNase T2 
(A and B) Urea gel of RNA40S digested with decreasing amounts of either RNaseT2 (A) or RNase A (B). One 





RNA40O fragments is shown (left, masses were determined by MALDI-TOF) and the corresponding MALDI peaks 
of a representative peak marked in green (right). (D) RNA40O was digested in vitro with RNase T2. The analysis 
was performed using HPLC and MALDI-TOF. All found fragment masses (based on the MALDI-TOF analysis) are 
shown and were assigned to the most likely ONs. All calculated and found masses are depicted as [M-H]-. (E) 
Shown are the structures of mononucleotide 2’,3’-cyclophosphates (left) and Mononucleotide 3’-phosphates 
(right). (F) RNA40S was digested with RNase T2 and analyzed by HPLC and MALDI-TOF. Shown are all possible 
fragments theoretically fitting to the found masses of the digest. The color code indicated the probability with 
which the masses could be assigned to the shown fragments. All fragment masses are shown as [M-H]-. (G) 
Depicted are the most likely assigned fragments from the analysis in (F). (H) All theoretically possible fragments 
of RNA40 digested with RNase T2 are shown assuming that the enzyme can only cleave between G and U. The 
ticks in front of each fragment indicate if it could be found in one of the MALDI-TOF analysis. 
Moreover, all ONs cleaved at their 3’ end had a 2’- 3’-cyclophosphate rather than a 3’-
phosphate configuration (Figure 4.5E). This is, however, in line with the published cleavage 
mechanism of RNase T2 suggesting a 2’- 3’-cyclophosphate configuration as an intermediate 
state which can then be hydrolyzed to an open 3’-phosphate (MacIntosh, 2011). Yet, 
hydrolysis seems to be quite inefficient under the used reaction conditions. Performing 
analogous experiments with RNA40S showed comparable results, well in line with the notion 
of RNase T2 cleaving RNA between guanosine and uridine (Figure 4.5G). Interestingly, the 
same 2’- 3’-cyclophosphate configuration at the 3’ end of cleaved fragments was found. 
Additionally, all possible fragments (according to their mass) were listed and color coded by 
their probability (Figure 4.5F). Like for RNA40O all uncertain fragments were allocated 
according to the unequivocally identified ONs. Taken together, assuming RNase T2 is only 
capable of cleaving between guanosine and uridine, 11 out of 14 possible fragments of 
RNase T2 digested RNA40 could be assigned by mass spectrometry (Figure 4.5H). 
To confirm the unique cleavage pattern of RNase T2 we repeated the degradation 
experiments, using RNase A instead of RNase T2. This analysis revealed, like already indicated 
by in vitro digested RNA40O, a fundamentally different cleavage pattern. RNase A 
preferentially cuts RNA after pyrimidines (uridine or cytidine), which is in line with the already 
published literature. As observed for RNase T2 degradation, fragments digested by RNase A 
were likewise terminated by a 2’- 3’-cyclophosphate structure (Figure 4.6A). As RNA40 does 
not have a very complex sequence and therefore is not allowing the investigation of the exact 
substrate specificity of RNase T2, we switched to 16 different ONs containing all possible 
dinucleotide combinations. The ONs were flanked by adenosines and had the following 
sequence: A4-NN-A2 (Figure 4.6B). Due to their asymmetry, the cleavage products could easily 
be analyzed by LC-MALDI-TOF (Figure 4.6C) and revealed cleavage of RNase T2 between 
guanosine and uridine (GU) as well as between adenosine and uridine (AU) residues with 
comparable efficiency. This renders the cleavage specificity of RNase T2 to purine uridine (RU). 





RNase T2 whereas the partially single stranded RNA P20-5M was readily cleaved (Figure 4.6D). 
This indicates, that RNase T2 is not capable of cutting base-pairing RNA but rather needs 
ssRNA as a template, providing a rationale as to why ONs like P20 do not exert TLR8 activity 
(Ablasser et al., 2009). Together, these results indicate that under the conditions tested, 
RNase T2 is preferentially cleaving ssRNA between purine and uridine (RU) residues resulting 
in 2’- 3’-cyclophosphate terminated fragments. 
Figure 4.6 RNase T2 cleaves RNA between purine bases and uridine 
(A) RNA40O was in vitro digested with RNase A and analyzed as described above. All found and calculated masses 
are depicted as [M-H]-. (B) To investigate the cleavage site of RNase T2, 16 ONs were digested carrying all possible 
dinucleotide combinations (A4NNA2) and analyzed by HPLC and MALDI-TOF. Of note, all ONs with uridine at the 
B1 site were cleaved between A and U but not between U and N. (C) HPLC chromatogram from the cleavage 
analysis in (G) corresponding to the ONs with the sequence GU, GG, AU and AA. (D) Urea gel of the in vitro 
digested ONs P20 and P20-5M are shown. P20 is a self-complementary RNA fragment forming a hairpin structure, 
whereas P20-5M is only partially self-complementary resulting in single stranded RNA stretches. One of two 





 Altered RNA catabolism in cellulo in the absence of RNase T2 
Once the cleavage site of RNase T2 was determined we wanted to address the question, how 
the enzyme is affecting RNA catabolism in cellulo. To this end, we designed a mass 
Figure 4.7 RNase T2 deficiency leads to altered RNA metabolism 
(A) Schematic overview of experimental workflow: BLaER1 cells were stimulated with RNA40S for 14 h, lysed and 
analyzed by liquid chromatography mass spectrometry (LC-MS). (B and C) Ctrl and RNASET2-/- cells were 
stimulated with RNA40S and analyzed by LC-MS. RNA40S derived metabolites are shown in (B) whereas 
endogenous ones are shown in (C). Data are normalized to Ctrl cells (note logarithmic scale). (D) Whole cell lysate 
of BLaER1 cells with indicated genotype was analyzed by LC-MS. All data are normalized to Ctrl cells. Statistical 






spectrometry approach to measure the abundance of specific metabolites generated by 
RNase T2, ranging from single nucleosides up to certain trinucleotides (Figure 4.7A). To 
distinguish between endogenous and stimulation derived fragments, cells were treated with 
RNA40S, as the backbone modification (oxygen atom is replaced with a sulfur atom) resulted 
in heavier metabolites allowing the identification of RNA40S derived fragments. To assign the 
found masses to the appropriate metabolite, we either made use of synthetic standards or of 
obtained data from RNA40 in vitro digests. This allowed us to unequivocally identify 
mononucleotides as well as di- or trinucleotides with a 2’-3’-cyclophosphate moiety from 
either endogenous origin or RNA40S degradation. 
The analysis of RNA40S derived metabolites containing a 2’-3’-cyclophosphate configuration 
showed only a slight drop of C>p and CC>p whereas G>p was decreased over 90% in the 
absence of RNase T2 (Figure 4.7B). Of note, the level of U>p and UU>p was also greatly 
reduced, whereas A>p could not be detected in either control or RNASET2-/- cells. The 
metabolites GG>p and AA>p could also not be detected, however, this is expected as they are 
Figure 4.8 Total metabolites of RNA40O stimulated Ctrl and RNASET2-/- cells 
BLaER1 cells of indicated genotypes were either unstimulated or stimulated with RNA40O. Cell lysates were 
analyzed by LC-MS. The mean of the highest vale was determined for each metabolite and data are depicted as 
a fraction thereof. Data are depicted as mean + SEM of three experiments. Statistical significance was calculated 





not contained in RNA40. Strikingly, the signal of UG>p and UUG>p was robust in control cells 
whereas the metabolites could barely or not be detected in the absence of RNase T2. 
Intriguingly, analyzing endogenous metabolites (non-sulfur backbone) in either RNA40S 
stimulated (Figure 4.7C) or unstimulated cells (Figure 4.7D), largely reflected the results 
obtained by RNA40S derived degradation products. Similar to RNA40S derived metabolites the 
level of endogenous C>p and CC>p was largely unaffected in the absence of RNase T2, whereas 
Figure 4.9 Deficiency in RNase A family enzymes leads to altered metabolism distinct from RNASET2-/- cells 
(A-C) RNASE1-/-, RNASE2-/- and RNASE6-/- BLaER1 cells were stimulated with RNA40S, lysed and analyzed by LC-
MS. RNA40S derived metabolites are shown and data are normalized to Ctrl cells (note logarithmic scale). All 
stimulations were carried out for 14 h. Data are depicted as mean + SEM of three independent experiments. 
Statistical significance was calculated using a Welch’s unequal variances t test: ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 





U>p, UU>p, UG>p and G>p were significantly reduced. While A>p, AA>p and GG>p could not 
be detected among RNA40S degradation products, they could readily be identified in the 
endogenous pool showing significant dependence on RNase T2. For UUG>p on the other hand, 
it was the other way around: while it could be detected after RNA40S stimulation, it was not 
found among the endogenous pool, indicating an important role during cell stimulation. 
However, mononucleotide levels were unaffected under either RNA40S stimulated or 
unstimulated conditions. These results offer insights about the origin of metabolites during 
the course of stimulation and their relative abundance in a RNase T2 dependent manner. 
However, they cannot provide information about the absolute increase of metabolites after 
stimulation compared to endogenous levels. 
To address this question, cells were stimulated with RNA40O to obtain metabolites 
indistinguishable from the endogenous pool, to monitor the global change of RNA degradation 
products in cellulo (Figure 4.8). This experiment revealed a moderate increase in metabolite 
levels of G>p, A>p, U>p and C>p (2.8-, 1.5-, 3.4-, and 1.9-fold) after RNA40 treatment as well 
as a RNase T2 dependence for G>p, A>p and U>p. Of note, U>p was less dependent on RNase 
T2 than G>p or A>p. As already observed in previous experiments, the level of C>p and CC>p 
was neither significantly altered after RNA stimulation nor in the absence of RNase T2. Levels 
of GG>p, AA>p and to a lesser extend UU>p were dependent on RNase T2, however, they were 
virtually unaffected by RNA40O stimulation. Intriguingly, the metabolites UG>p and UUG>p 
could almost exclusively be detected after RNA40O stimulation and were completely 
dependent on RNase T2. Stimulation resulted in 33-times higher UG>p levels, whereas UUG>p 
could not even be detected in unstimulated cells. This indicates an important role for both 
metabolites in the course of RNA stimulation. Of note, loss of RNase A family members like 
RNASE2 or RNASE6 did not alter RNA40S derived metabolites in any fashion (Figure 4.9B and 
C), solely RNASE1 deficient cells showed a drop in C>p and CC>p levels (Figure 4.9A). Together 
these results indicate a critical role of RNase T2 in generating certain metabolites with a 2’-3’-
cyclophosphate moiety from either endogenous or exogenous origins. Most strikingly, UG>p 







 A minimal motif for TLR8 activation 
Figure 4.10 A minimal motif for TLR8 activation 
(A and B) BLaER1 cells of indicated genotype were stimulated with DNA-RNA hybrids (dN)6UUNN(dN)8. The four 
middle bases are ribonucleotides which are flanked by random deoxyribonucleotides. As control, cells were 
stimulated with TL8-506, R848 and LPS. All supernatants were harvested after 14 h and analyzed by IL-6 ELISA. 
(C) BLaER1 cells of indicated genotype were stimulated with the shown DNA-RNA hybrid oligos and analyzed 
after 14 h by LC-MS. The mean of the highest vale for each dataset was determined and data are depicted as 
fractions thereof. Data are depicted as mean + SEM of three independent. Statistical significance was calculated 






The results above indicate a critical role of UG>p in the course of TLR8 activation. As RNA40 is 
harboring four GU dinucleotides in its sequence, we switched to oligos containing a minimal 
motif for TLR8 activation flanked by non-stimulatory sequences. To this end, it was already 
published that UUGU in the context of deoxyribonucleotides ((dN)6UUGU(dN)8) leads to pro-
inflammatory cytokine release in human myeloid cells, downstream of TLR8 activation 
(Forsbach et al., 2008). These results are in line with our previous finding, that RNase T2 is 
capable of cleaving RNA between guanosine and uridine residues explaining its TLR8 agonistic 
activity. As this hybrid ON offers an excellent platform to investigate the minimal motif for 
TLR8 activation, we stimulated BLaER1 cells with a phosphorothioate stabilized version of it. 
Indeed treating cells with (dN)6UUGU(dN)8 led to IL-6 release in a RNase T2 and TLR8 
dependent manner, albeit at lower level then RNA40 (Figure 4.10A). Exchanging the terminal 
uridine by any other possible ribonucleotide or a random deoxyribonucleotide confirmed the 
previously found sequence specificity of RNase T2, as all of them rendered the ON non-
immunostimulatory. This underlines the importance of uridine at the second position of the 
cleavage site, being essential to render the ON TLR8 agonistic. As the previous published data 
showed immunostimulatory effects not only for GU- but also AU-rich ONs the question arouse, 
whether AU-rich sequences also lead to the release of pro-inflammatory cytokines in a 
RNase T2 and TLR8 dependent manner. To this end, we modified the RNA bases within the 
hybrid ON to UUAU or UUAA and tested them in stimulation assays. In line with our previous 
results only UUAU but not UUAA resulted in RNase T2 as well as TLR8 dependent induction of 
pro-inflammatory cytokines (Figure 4.10B). To further support these data, ON derived 
metabolites were measured by LC-MS in cellulo. As expected, we could observe increased G>p 
and UG>p levels exclusively in cells stimulated with UUGU, in a completely RNase T2 
dependent fashion (Figure 4.10C). The same could be observed for adenosine containing 
oligos: only cells stimulated with UUAU but not UUAA showed RNase T2 dependent increase 
of A>p and UA>p levels. Intriguingly, U>p levels were largely uncoupled from the stimulatory 
capacity of used ONs. Stimulation with the immunostimulatory UUGU ON led to equal U>p 
level compared to the non-activating UUAA ON. Furthermore, U>p level of UUAA was largely 
independent of RNase T2, whereas for UUGU a clear dependence could be observed. In line 
with these results, UUAU led to the highest induction of U>p in a partially RNase T2 dependent 
manner. Together this data suggests that, UURU is a minimal motif for RNase T2 dependent 
TLR8 activation. Furthermore, the release of at least a dinucleotide with the sequence UR>p 
seems to be critically required for TLR8 activation, however, exclusively increased U>p level 





 RNase T2 degradation products bypass the lack of RNase T2 to exert TLR8 
agonism 
Some years ago the crystal structure of TLR8 was solved revealing the binding of YG as well as 
YYG di- or trinucleotides with a 2’- 3’-cyclophosphate configuration to the second pocket of 
TLR8 (Figure 4.11) (Tanji et al., 2015). They found, that the cyclophosphate structure of these 
oligonucleotides was coordinated by the amino bond of residue L474. These results, together 
with our previous data are in line with the notion, that RNase T2 derived metabolites could 
play a critical role in TLR8 activation. Therefore, we hypothesized that RNase T2 is essential to 
generate ligands with (Y)YG>p motif, fitting into the second binding pocket of TLR8. To test if 
TLR8 can be directly activated by delivering second pocket ligands, we digested RNA40S in vitro 
with either RNase T2 or RNase A and stimulated BLaER1 cells with the respective degradation 
mixture (Schematic overview, Figure 4.12A). Of note, for RNA40S digests with RNase A, three 
different concentrations were used reaching from complete degradation (+++) to partial 
degradation with distinct bands (+) (Figure 4.12B), whereas for RNase T2 only undercutting 
conditions were used. As expected, stimulation with untreated RNA40S could potently 
stimulate Ctrl cells, whereas RNASET2-/- and TLR8-/- cells showed no IL-6 release (Figure 4.12C, 
gray bars). However, after in vitro digest with RNase T2, the degradation products of RNA40S 
were able to induce a robust immune response in RNASET2-/- cells and even boosted IL-6 levels 
in Ctrl cells. In line with previous results, the stimulation was completely TLR8 dependent 
(Figure 4.12C, green bars). For RNase A, on the other hand, only the lowest enzyme 
concentration (+), containing full-length as well as long RNA40S fragments, was still capable of 
inducing comparable IL-6 level, however, the stimulation was significantly dependent on 
Figure 4.11 Crystal structure of the second TLR8 binding pocket 
Part of the TLR8 crystal structure showing the second binding pocket of the protein bound to UG>p (PDB, 4R07). 
Yellow dashed lines indicate hydrogen bonds whereas green lines show 𝜋-𝜋-interactions. The following color 






RNase T2 and TLR8 (Figure 4.12C, magenta bars). This indicates that RNase A degradation 
products are not capable of directly activating TLR8, but that intracellular RNase T2 is digesting 
either remaining full length RNA40S or at least large fragments of it, to generate TLR8 ligands.  
 
Figure 4.12 RNase T2 degradation products can bypass RNase T2 deficiency 
(A) Schematic overview of experimental setup: RNA fragments were digested with either RNase T2 or RNase A 





concentrations of RNase A. (C) BLaER1 cells were either stimulated with full length RNA40S or digested RNA40S 
from (B). Control stimulations are shown on the right. (D) Urea gel of the full length and RNase T2 digested 
(AC)7UUGUCU. (E) BLaER1 cells were stimulated with either full length or RNaseT2 digested (AC)7-UUGUCU. 
Respective control stimulations are shown on the right. (F) List of ONs used for the stimulation in Figure 4.13. 
Arrows indicate RNase T2 cleavage site. (G) Urea gel of the following fragments: (dAdC)7UUGUCU, (dAdC)7UUG, 
(dAdC)7UU and (dAdC)8. (H) Urea gel of full length and RNase T2 digested (dAdC)7UUGUCU. (I) BLaER1 cells were 
stimulated with full length and RNase T2 digested (dAdC)7UUGUCU (0.9 µg/condition). Respective controls are 
shown at the right. Data are depicted as mean + SEM of three independent experiments or one of two 
representative gels. Statistical significance was calculated using two-way ANOVA: ****p ≤ 0.0001; ***p ≤ 0.001; 
**p ≤ 0.01; *p ≤ 0.05; ns, not significant. 
To further study the generation of second pocket ligands for TLR8, we switched to a more 
reductionistic ON with the following sequence: (AC)7UUGUCU. According to our cleavage 
analysis this ON harbors only a single cutting site for RNase T2 resulting in an UUG>p 
terminated RNA fragment and the trinucleotide UCU (Figure 4.12D). Experiments showed, 
that its stimulatory capacity was very similar to RNA40: the full-length ON could stimulate 
BLaER1 cells in a RNase T2 and TLR8 dependent manner, whereas the in vitro digest with 
RNase T2 could rescue its phenotype in RNASET2-/- cells (Figure 4.12E). Next, we wanted to 
test if UUG terminated ONs, as they are generated by RNase T2, can exert TLR8 activity on 
their own and how their stimulatory capacity is influenced by their 3’ phosphate configuration. 
To this end, we tried to purify (AC)7UUG>p by high-performance liquid chromatography (HPLC) 
from RNase T2 digests, however, it turned out to be nearly impossible due to the huge number 
of diastereomers caused by phosphorothioate linkages. Therefore, we exchanged the inert 
part of (AC)7UUGUCU by phosphodiester linked deoxynucleotides resulting in 
(dAdC)7UUGUCU (Figure 4.12F and G). Similar to the phosphorothioate stabilized ON, 
degradation of (dAdC)7UUGUCU by RNase T2 showed only one large degradation product, as 
the trinucleotide cannot be detected on the urea gel (Figure 4.12H). Furthermore, stimulation 
of BLaER1 cells with in vitro digested (dAdC)7UUGUCU did rescue RNase T2 but not TLR8 
deficiency (Figure 4.12I). Having established the phosphodiester ON, we investigated the 
stimulatory capacity of two shortened derivates of (dAdC)7UUGUCU terminating with either 
UUG or UU. Whereas the UUG terminated fragment was able to stimulate TLR8, the shorter 
UU variant was completely inert (Figure 4.13A, insert). Intriguingly, stimulation with UUG was 
dramatically weaker compared to ex cellulo digested full-length ON and surprisingly partially 
dependent on RNase T2 (Figure 4.13A). We hypothesized, that the lower stimulatory capacity 
could have two possible reasons: on the one hand the lacking trinucleotide UCU could serve 
as uridine donor and therefore be needed for first pocket ligand generation. In this scenario 
uridine is potentially released by another lysosomal RNase, possibly also in cooperation with 
RNase T2. On the other hand, the stimulatory capacity could be influenced by the 3’ 





phosphate moiety, whereas the in vitro digested ON has a 2’- 3’-cyclophosphate structure. To 
address this question, we stimulated BLaER1 cells with (dAdC)7UUG, terminated with either 
an OH group, a 3’-phosphate or a 2’- 3’-cyclophosphate. As synthesizing 2’- 3’-cyclophosphate 
structures is chemically very challenging and not commercially available, we generated it 
enzymatically: after in vitro digesting (dAdC)7UUGUCU the two degradation products were 
separated by HPLC, obtaining highly pure (dAdC)7UUG>p. To exclude possible influence of 
HPLC purification on cell stimulation, all commercially available ONs were also purified 
according to the same protocol. To address the second scenario involving the release of 
uridine as first pocket ligand, all stimulations were performed with and without co-delivery of 
Figure 4.13 A purine terminated fragment and uridine are required for robust TLR8 activation 
(A) BLaER1 cells were stimulated with the ONs from (Figure 4.12F) (top panel). (B) ONs from (Figure 4.12F) 
(bottom panel) were purified by HPLC and used for BLaER1 stimulation. To obtain cyclophosphate terminated 
(dAdC)7UUG>p the parental ON (dAdC)7UUGUCU was digested by RNase T2 and subsequentially purified by HPLC. 
Control stimuli are shown below. All ONs were either transfected alone or together with the DNA-RNA hybrid 
(dN6)UUAA(dN8) (1.2 µg) which served as uridine donor. All stimulations were carried out for 14 h and IL-6 ELSA 
was measured afterwards. Data are depicted as mean + SEM of three independent experiments. Statistical 






a uridine donor. Therefore, we exploited the already characterized DNA-RNA hybrid 
(dN)6UUAA(dN)8, which had no stimulatory capacity but led to equal amounts of catabolic U>p 
compared to TLR8 agonistic ONs. These experiments revealed a rather limited induction of 
pro-inflammatory cytokines after stimulation with either of the three UUG terminated 
fragments, reaching only 10-20% of the in vitro digested ON (Figure 4.13B). However, co-
delivering an uridine donor ((dN)6UUAA(dN)8), which itself exerted no TLR8 activation, led to 
significantly increased IL-6 production, now equaling in vitro digested (dAdC)7UUGUCU. Of 
note, these stimulations are largely independent of RNase T2. Intriguingly, the 2’- 3’-
cyclophosphate moiety was beneficial compared to other 3’ configurations, leading to 
approximately two times increased cytokine levels. Together these results demonstrate, that 
delivering G-terminated fragments can bypass the requirement for RNase T2 and directly 
activate TLR8. Furthermore, G-terminated fragments are occupying the second binding pocket 
of TLR8 and need a certain uridine level for potent activation. 
 Staphylococcus aureus detection in myeloid cells depends on RNase T2 
upstream of TLR8 
By using ONs with diverse sequences, we have so far been able to show the cleavage pattern 
of RNase T2 and the downstream activation mechanism of TLR8. To investigate the 
involvement of RNase T2 in sensing complex pathogens, we stimulated BLaER1 cells with 
Staphylococcus aureus, as it was previously published that myeloid cells mainly exploit TLR8 
to detect these bacteria (Bergstrom et al., 2015; Kruger et al., 2015). To this end, in vitro 
incubation of S. aureus derived total RNA with RNase T2 showed potent cleavage (Figure 4.14A 
and B). To investigate if RNase T2 is involved in TLR8 activation upon S. aureus infection in 
cellulo, we first stimulated BLaER1 cells with purified bacterial RNA (Figure 4.14C). Indeed, the 
stimulation was, like with RNA40, mainly dependent on RNase T2 upstream of TLR8, however, 
we observed some residual activity under these conditions. This scenario can most likely be 
explained by the fact, that complex RNA molecules can engage different immune pathways. 
To take this one step further, we next stimulated BLaER1 cells with live S. aureus at different 
multiplicity of infection (MOI) (Figure 4.14D). This showed potent induction of pro-
inflammatory cytokines upon cell infection, which was significantly dependent on RNase T2 
and TLR8 (Figure 4.14E). To investigate if S. aureus RNA is degraded by RNase T2 in cellulo, we 
metabolically labeled the pathogen by using heavy isotope containing growth medium (15N) 
and analyzed isotope-labeled metabolites in BLaER1 cells upon infection (Figure 4.15A and C). 





MOIs tested (Figure 4.15B). By analyzing stable-isotope-labeled metabolites we could detect 
all four ribonucleotides derived from degradation of S. aureus RNA, however, their abundance 
was independent of RNase T2 (Figure 4.15D). Yet, in line with the cleavage specificity of 
RNase T2, the metabolites G>p and A>p could only be detected in control but not in RNase T2 
deficient cells. U>p and C>p on the other hand could neither be detected in control nor in 
Figure 4.14 RNase T2 is critically involved in S. aureus detection upstream of TLR8 
(A) Schematic overview of experimental procedure: S. aureus was grown over night harvested and total RNA was 
isolated. (B) Full length and RNase T2 digested S. aureus RNA was analyzed by Bioanalyzer. (C) BLaER1 cells were 
stimulated with either RNA40S or S. aureus RNA. Controls are shown at the right. (D) Schematic overview of 
BLaER1 stimulation with live S. aureus. In brief: S. aureus was grown over night, washed and used for stimulation 
at different MOI. 1 h later gentamicin was added to kill remaining extracellular bacteria. After 14 h supernatant 
was harvested and IL-6 ELISA was measured. (E) S. aureus stimulation of BLaER1 cells and associated controls. 
Data are depicted as mean + SEM three (E) or four (C) independent experiments. Statistical significance was 





RNASET2-/- cells. Of note, only fully labeled metabolites were taken into account, as they were 
by far the most abundant species. Together these results indicate that recognition of complex 
RNA molecules, derived from bacteria like S. aureus, is mediated by RNase T2 degradation 
upstream of TLR8. This shows a very important role of specifically RNase T2 in the course of 
recognizing bacterial infections.  
Figure 4.15 S. aureus derived RNA metabolites with a cyclophosphate moiety depend on RNase T2 
(A) Schematic overview of BLaER1 stimulation with 15N-labeled S. aureus: Bacteria were grown over night and 
used for cells stimulation. After 1 h gentamicin was added and another 14 h later the supernatant was analyzed 
by IL-6 ELISA. (B) BLaER1 stimulation with different MOI of live 15N-labeled S. aureus. Controls are shown on the 
right. (C) Schematic overview of generating 15N-labeled S. aureus and the subsequent stimulation of BLaER1 cells. 
Cells were analyzed by LC/MS. (D) Metabolites of BLaER1 cells stimulated with 15N-labeled S. aureus were 
analyzed. 15N-labeled metabolites are shown (note logarithmic scale). Data are depicted as mean + SEM of two 
(D) or three (B) independent experiments. Statistical significance was calculated using two-way ANOVA: ****p ≤ 






Pathogens like bacteria or viruses invade cells of the human body every day challenging the 
immune system. Thus, the body requires a tightly regulated immune response, which is strong 
enough to defeat invading pathogens, but without causing severe tissue damage or chronic 
inflammation. TLRs, a group of pattern recognition receptors, are crucially involved in innate 
immune defense by recognizing all sorts of molecules derived from pathogens, including DNA, 
RNA and bacterial cell wall components (PAMPs). To defend against many different bacterial 
and viral infections, ssRNA recognition inside the lysosome by TLR7/8 is essential. Despite this 
important function, their mode of action is not fully understood. This is especially true for 
TLR8, as the receptor can, under physiological conditions, not be activated by RNA ligands in 
mice (Gorden et al., 2006; Hemmi et al., 2002). However, the crystal structure of both proteins 
was recently solved and revealed two distinct binding pockets in either receptor (Tanji et al., 
2015; Zhang et al., 2016). In both cases the first pocket is occupied by a single nucleotide 
(uridine for TLR8 and guanosine for TLR7), whereas the second pocket binds to at least a di- 
or trinucleotide. Yet a minimal motif or the exact identity of the second pocket ligand remains 
elusive. Furthermore, the studies showed that occupation of the first pocket by a high affinity 
molecule like R848 is sufficient for receptor activation, nevertheless under physiological 
conditions the second pocket is essential. It was previously shown that DNase II is critically 
required upstream of TLR9 for ligand generation (Chan et al., 2015), however it is tempting to 
assume that a protein with RNase activity is needed upstream of TLR7/8 to degrade complex 
RNA molecules into appropriate ligands for receptor activation. In this study we exploited the 
BLaER1 cell system to investigate the sequence specificity and activation mechanism of TLR8, 
which up to that point was poorly studied due to the lack of a suitable model system. To this 
end, BLaER1 cells can easily be modified in their B-cell state, using the CRISPR/Cas9 system 
and then be trans-differentiated into macrophage like cells to investigate their phenotype. In 
this regard, we systematically knocked out RNases possibly acting upstream of TLR8, as well 
as the receptor itself. Realizing RNase T2 is critically involved in TLR8 ligand generation, we 
analyzed its degradation pattern in vitro and in cellulo by LC/MS. Furthermore, we investigated 
the requirement of RNase T2 and TLR8 during Staphylococcus aureus infections. 
 TLR7 and TLR8 recognize RNA inside the endolysosome 
To investigate TLR8 activation we first established the BLaER1 human cell system. RNA 
sequencing data revealed that the receptors TLR4, TLR7 and TLR8 are significantly upregulated 
upon trans-differentiation of these cells (Figure 4.1A). As expected, stimulation of TLR7 and 





was dependent on TLR7 and 8 (Figure 4.1B). Intriguingly, stimulation with RNA40 
(phosphorothioate as well as phosphodiester backbone) was completely dependent on TLR8 
but not on TLR7, rendering BLaER1 cells a perfect platform to investigate TLR8 activation 
(Figure 4.1C). To specifically deliver RNA ONs into the endolysosomal compartment, p-L-
arginine (pR) was used as a transfection reagent (Ablasser et al., 2009), as lipofectamine 2000 
only led to minor IL-6 release (Figure 4.2A). Of note, for most experiments during this study 
the phosphorothioate stabilized ligand RNA40S was used as it is more stable against 
degradation. Except for RNA40, we also tested the already published ONs P20 and P20-5M 
(Ablasser et al., 2009). P20, is forming a hairpin structure and was not able to stimulate either 
Ctrl, TLR7 or TLR8 deficient cells. However, partially destroying the double stranded structure 
of P20 by altering its sequence (P20-5M), rendered the ON immunostimulatory in a completely 
TLR8 dependent fashion (Figure 4.2E). This clearly indicates that only single stranded but not 
double stranded RNA is essential for TLR8 activation. Together these results establish the 
BLaER1 trans-differentiation system a good model to investigate TLR8 activation as well as the 
identity of its ligands. 
 RNase T2 is generating unique ligands for TLR8 
The systematic KO of endolysosomal RNases revealed, that RNA40 stimulation is completely 
dependent on RNase T2, suggesting that it is critically responsible for TLR8 ligand generation 
(Figure 4.3). At first glance this seems rather surprising as several RNases can be found in 
humans, many of which are located inside the endolysosomal compartment. However, 
RNase T2 is the only family member of the RNase T2 superfamily found in humans. Generally, 
endoribonucleases can be divided into three distinct families: RNase A, RNase T1 and 
RNase T2. All members of these families enter the secretory pathway and can therefore be 
found in the endolysosomal compartment as well as in the extracellular space. Furthermore, 
they all belong to the group of transferase-type endoribonucleases, sharing a similar cleavage 
mechanism: in a first step the substrate is cleaved generating a 2’-3’-cyclophosphate 
intermediate state, before it is hydrolyzed in a second step, resulting in an open 3’-phosphate 
structure (MacIntosh, 2011). Although the three families share the same mode of action they 
can predominantly be found in different kingdoms of life. Whereas RNase A enzymes are very 
diverse in the vertebrate lineage, RNase T1 enzymes are present in fungi and bacteria. 
RNase T2 enzymes on the other hand can be found in all kingdoms of life except Archaea. 
Unlike enzymes from the RNase A family, which have undergone extensive duplications and 
diversifications in humans (13 different genes), only one member of the RNase T2 family is 
expressed. Like humans most animals express only one RNase T2 enzyme, however, the family 





indicates an important housekeeping function of RNase T2 enzymes. In zebrafish for example, 
knocking out RNase T2 leads to rRNA accumulation inside the lysosomal compartment of cells 
of the central nervous system (Haud et al., 2011). This indicates its involvement in ribosome 
turnover, a process called ribophagy that prevents the accumulation of RNA inside the cells. 
Structural analysis of RNase T2 enzymes revealed two distinct nucleotide binding pockets, the 
B1 and B2 site, determining their substrate specificity (MacIntosh, 2011). In bitter gourd, a to 
human RNase T2 structurally very related RNase called MC1 was found, preferentially binding 
to uridine at its B2 site. As the B1 site seems to be quite tolerant to all bases, the cleavage site 
of MC1 appears to be 5’-NU-3’ (Numata et al., 2003; Suzuki et al., 2000). Of note, the base 
coordinating amino acids of the B2 pocket are orthologous between MC1 and human 
RNase T2 (Thorn et al., 2012), suggesting similar binding patterns of the two proteins. Indeed, 
all results obtained by in vitro digestion of RNA40 showed cutting of RNase T2 exclusively 
before uridine residues, whereas RNase A showed a distinct degradation pattern. By analyzing 
16 ONs with the sequence A4NNA2, harboring all possible dinucleotide combinations, we could 
specify RNase T2 cleavage site to purine-uridine (5’-RU-3’) (Figure 4.5 and 4.6). The non-
redundant action of RNase T2 strongly indicates, that the enzyme generates purine 
terminated RNA fragments with a 2’-3’-cyclophosphate moiety, occupying the second binding 
pocket of human TLR8. Intriguingly, lysosomal ribonucleases of the RNase A family seem to 
generate degradation products incompatible with TLR8 activation. Hence, it seems like hTLR8 
has evolved to specifically recognize RNase T2 degradation products leading to a downstream 
immune response. 
 RNase T2 alters RNA metabolism in cellulo 
Up to that point, little was known about the identity of lysosomal RNA degradation products 
and the influence of enzymes like RNase T2 on them. To this end, we investigated cellular RNA 
metabolite levels under steady state as well as stimulated conditions. We aimed to evaluate 
the involvement of RNase T2, specifically if the enzyme is only impacting on RNA degradation 
products derived from foreign RNA, or if it is also influencing the steady-state pool. To 
distinguish endogenous from exogenous metabolites we stimulated with RNA40S as due to 
the phosphorothioate backbone its degradation products can be distinguished from cellular 
metabolites by mass. This renders RNA40S degradation products an excellent proxy for the 
catabolic activity of lysosomal enzymes like RNase T2. 
Analyzing metabolite levels from either endogenous or exogenous origin by LC/MS revealed a 
significant drop of G>p and A>p as well as G>p- and A>p-terminated fragments in RNASET2-/- 
cells. As according to our results RNase T2 cleaves after purines we assumed, that C>p and 





enzymes from the RNase A family, as they were published to cleave after pyrimidines. As 
expected, C>p levels were unchanged in RNASET2-/- cells, whereas they were slightly 
decreased in the absence of RNase 1. U>p levels on the other hand where significantly 
decreased in RNASET2-/- cells. Theoretically, the absence of RNase T2 can affect U>p levels up 
to 50% as the enzyme is cleaving upstream of uridine, however, why U>p levels were affected 
beyond that is not clear. A possible explanation would be, that RNase T2 is accepting uridine 
in its B1 pocket but with much lower affinity, which would explain why we did not observe 
this in our under-cutting experiments. Furthermore, it is possible, that the activity of RNase T2 
is also affected by other factors than the substrate specificity in cellulo. However, these results 
show a reduced lysosomal concentration of purine terminated fragments as well as uridine in 
the absence of RNase T2 (Figure 4.7). By stimulating cells with RNA40O, we could also analyze 
the global change of metabolites in cellulo, showing very similar results. G>p, A>p and U>p 
levels were increased about 2-3-fold upon stimulation and were nearly completely dependent 
on RNase T2, whereas C>p levels were largely unaffected. The same pattern could be observed 
for the dinucleotides GG>p, AA>p, UU>p and CC>p. Intriguingly, UG>p and UUG>p were only 
present after stimulation and completely dependent on RNase T2, implicating an important 
role of these metabolites in the course of TLR8 activation (Figure 4.8). 
These data were also supported by stimulation with more sequence restricted RNA ONs. To 
further investigate the cleavage behavior of RNase T2 in cellulo we stimulated our cells with 
DNA-RNA hybrid ON, which were published to exert TLR8 activity (Forsbach et al., 2008). The 
ONs harbor four RNA bases in the middle of their sequence, flanked by random DNA bases. As 
indicated by our previous results, only DNA-RNA hybrids containing the sequences UUGU or 
UUAU were able to stimulate BLaER1 cells, in a RNase T2 and TLR8 dependent manner. 
However, if the last uridine of UUGU was exchanged by any other possible nucleotide (G, A, C 
or dN) no TLR8 activation could be observed (Figure 4.10A and B). Analyzing ON derived 
metabolites in cellulo could explain this scenario: G>p as well as UG>p were only released from 
ONs containing UUGU but not UUGA, which was completely dependent on RNase T2. The 
same is true for the metabolites A>p and UA>p which were found in cells stimulated with 
UUAU but not UUAA. Intriguingly, the release of U>p was partially uncoupled from the ON 
sequence as well as from RNase T2. We found the amount of U>p in UUGU and UUAA 
stimulated cells was equal and largely independent of RNase T2, demonstrating that the sole 
increase of U>p under stimulation conditions is not sufficient to activate TLR8. However, it 
renders UUAA a perfect U>p donor without activating the receptor. Taken together these 
results show, that RNase T2 is critically involved in the generation of purine terminated 
fragments and that especially dinucleotides like UG>p and UA>p are needed for TLR8 
activation. This is in line with the notion that at least a dinucleotide is needed to occupy the 





 Mechanism of TLR8 activation downstream of RNase T2 
As TLR8 has two distinct pockets it is important to sort out which of them is occupied by 
RNase T2 degradation products and if the binding order matters. Interestingly, the occupation 
of the first binding site by small chemical compounds like R848 is sufficient for TLR8 activation, 
whereas under physiological conditions always both pockets seem to be occupied. The critical 
involvement of RNase T2 in TLR8 ligand generation became clear by in vitro digestion 
experiments. Transfecting BLaER1 cells with RNase T2 digested RNA was able to rescue 
RNase T2 deficiency, however, the stimulation was still TLR8 dependent. Delivering RNase A 
digested RNA40S on the other hand was not capable of bypassing RNase T2 deficiency. Of 
note, the stimulatory capacity of degradation mixtures incubated with the lowest amounts of 
RNase A in control cells, can be explained by the undercutting conditions. It results in 
remaining full-length RNA fragments which can intracellularly be cleaved by RNase T2, 
generating appropriate TLR8 ligands (Figure 4.12A-C). 
According to literature, the second pocket of TRL8 is preferentially occupied by guanosine 
terminated di- or trinucleotides of which the other bases are mainly pyrimidines (especially 
uridine) (Tanji et al., 2015). This together with the observed cleavage of RNase T2 between 
purine and uridine strongly indicates, that the enzyme is mainly generating ligands for the 
second pocket of TLR8. However, as the protein is cleaving upstream of uridine it is most likely 
also enhancing the generation of free uridine which can then occupy the first pocket of the 
receptor. Indeed, we could observe that RNA derived (U)UR>p fragments were RNase T2 
dependent and significantly affecting TLR8 activity. In fact, our experiments suggest RNase T2 
being the only endolysosomal RNase capable of generating the afore mentioned 3’-termini, 
explaining its non-redundant mode of action. As an additional feature, RNase T2 was mainly 
generating RNA fragments with a 2’-3’-cyclophosphate moiety. Yet, it turned out that the 
cyclic phosphate at the 3’ end is neither needed nor sufficient for TLR8 activation. 
Nevertheless, the cyclophosphate led to an about 2-fold increased release of pro-
inflammatory cytokines compared to RNA fragments with 3’-OH or classical 3’-phosphate 
termini (Figure 4.13). The first pocket of TLR8 on the other hand binds to uridine and is 
ultimately leading to TLR8 activation. Even though R848 can directly activate TLR7 and TLR8 
by only occupying their first pocket, under physiological conditions RNase T2 generated 
(U)UR>p fragments play a crucial role in receptor activation. Of note, due to RNase T2 cleaving 
upstream of uridine, RNASET2-/- cells showed a 4-fold reduced U>p level under steady state 
condition which was even 15-fold reduced after RNA stimulation (Figure 4.8). To this end, 
stimulation of BLaER1 cells with only a second pocket ligand like (dAdC)7-UUG resulted in 
significantly decreased IL-6 production compared to stimulation with in vitro digested (dAdC)7-





that the sole delivery of a second pocket ligand is not sufficient for TLR8 activation, whereas 
the co-delivery of a uridine donor like the UCU fragment is leading to robust downstream 
signaling. Indeed, the weaker activation of the second pocket ligand (dAdC)7-UUG could be 
overcome by co-delivering a non-stimulatory uridine donor like (dN)6UUAA(dN)8. As shown 
before stimulation with this ON led to comparable uridine levels as TLR8 agonistic RNAs but 
without the release of pro-inflammatory cytokines (Figure 4.10), however, together with 
(dAdC)7-UUG the stimulatory capacity was equal to in vitro digested (dAdC)7-UUG↓UCU. 
These results clearly show that sufficient amounts of uridine from exogenous origin are 
critically required for TLR8 activation. Of note, the sole release of uridine from complex RNA 
molecules is not sufficient to activate TLR8 and can also be found independently of RNase T2. 
All in all, RNase T2 is critically required for TLR8 dependent recognition of complex RNA 
molecules. Dictated by its substrate specificity (RU) the enzyme is essential for the generation 
of catabolic uridine occupying the first pocket of TLR8, however, this process includes enzymes 
from the RNase A family cleaving downstream of uridine. On the other hand, RNase T2 is non-
redundantly required for the generation of purine terminated fragments occupying the 
second pocket of TLR8. Together the results suggest that the second pocket ligand is 
allosterically controlling the binding of uridine to the first pocket, which is an important 
regulatory step under natural stimulation conditions. Of note, even though the 2’-3’-
cyclophosphate moiety is neither required nor sufficient for TLR8 activation, it significantly 
increases the stimulatory capacity of purine terminated RNA fragments. 
 RNase T2 is involved in pathogen sensing 
After investigating the RNase T2 mediated activation mechanism of TLR8 by synthetic ONs, we 
changed to a more natural system – stimulating with living pathogens. To this end, we infected 
BLaER1 cells with Staphylococcus aureus, a gram-positive bacterium to avoid activation of 
TLR4 by bacterial cell wall components (LPS). Furthermore, the pathogen is well adapted to its 
human host and leads to sever diseases like endocarditis, bacteraemia and osteomyelitis. 
Especially resistant strains like Methicillin- resistant Staphylococcus aureus (MRSA) represent 
a big threat, as they became a leading cause of health care associated infections. MRSA 
induced bacteraemia for example leads to a mortality rate of 15-50%, even with intensive 
medical attention (Turner et al., 2019). Hence, it is of great interest to further investigate 
cellular pathways and mechanisms associated with the recognition of pathogens like S. aureus. 
Before stimulating with living bacteria, we tested purified S. aureus RNA. These experiments 
showed potent degradation of S. aureus RNA by RNase T2 and robust IL-6 production upon 





living bacteria mirrored these results: the bacteria induced a strong immune response via the 
RNase T2-TLR8 route, leading to the release of pro-inflammatory cytokines. These data clearly 
show that TLR8 is critically involved in the recognition of complex pathogens like S. aureus, 
however, it also involves RNA degradation by RNase T2 to generate appropriate ligands for 
receptor activation (Figure 4.14). Furthermore, we also analyzed S. aureus derived RNA 
degradation products in cellulo. To this end, bacteria were labeled with the heavy isotope 15N 
Figure 5.1 Activation mechanism of TLR8 downstream of RNase T2 
Bacteria as well as viruses are often entering the cell via the endolysosomal rout or are taken up by 
phagocytosis. In both cases foreign RNA is ending up in the endosomal or lysosomal compartment. These RNA 
fragments can be recognized by the cell leading to the release of pro-inflammatory cytokines and interferons. 
In humans TLR8 is one of the RNA recognizing receptors. It consists of an endolysosomal LRR domain, one 
transmembrane domain and a cytoplasmic TIR domain. Furthermore, it has two distinct RNA binding pockets 
located inside the LRR domain. We found, that RNase T2, the only representative of the RNase T2 family present 
in humans, is critically involved in TLR8 activation. The enzyme is cleaving RNA between purine and uridine 
residues leaving a 2’-3’-cyclophosphate structure at the 3’-end. These R>p terminated fragments can engage 
the second pocket of TLR8, allosterically controlling uridine binding. The occupation of the first pocket by 
uridine is ultimately activating the receptor facilitating downstream signaling. The necessary uridine can either 
derive from the steady state pool or be released from foreign RNA fragments requiring the help of enzymes 





prior to stimulation, which allowed us to distinguish between endogenous and exogenous 
metabolites (Figure 4.15). Analysis of S. aureus RNA derived degradation products showed 
equal levels of ribonucleotides (G, A, U and C) in Ctrl and RNase T2 KO cells. Yet, the 
metabolites G>p and A>p, carrying a 2’-3’-cyclophosphate moiety, could exclusively be found 
in control cells. At the same time, we were unable to detect U>p or C>p, in either control or 
RNase T2 KO cells. Due to the high complexity of 15N-labeled metabolites it was not possible 
to assign longer RNA fragments than single nucleotides, however, the results suggest that 
RNase T2 cleaves S. aureus RNA in cellulo generating G>p- and A>p-terminated RNA fragment, 
which are needed for TLR8 activation. In conclusion the RNase T2-TLR8 route seems to be 
critically involved in the recognition of complex RNA molecules in the course of bacterial 
infections. 
Taken together in this study we could identify RNase T2 as a critical factor acting upstream of 
TLR8. Whereas the majority of RNases belongs to the RNase A family and cleaves after 
pyrimidines, RNase T2 has a unique substrate specificity, cleaving between purine bases and 
uridine. This generates RNA fragments with a 2’-3’-cyclophosphate configuration binding to 
the second pocket of TLR8. Furthermore, it leaves a second RNA fragment with a 5’-uridine, 
which can be further cleaved by other RNases to release uridine needed for the first pocket. 
Therefore, RNase T2 not only generates ligands for the second pocket of TLR8 but is also 
involved in uridine release. As previously published, the occupation of the first pocket is crucial 
for TLR8 activation. As such our data suggests, that the second pocket of TLR8 is occupied first, 
increasing the binding affinity of uridine to the first pocket. The binding of uridine then 
ultimately leads to TLR8 activation and downstream signaling. The uncovered pathway is 
playing a critical role in detecting infections with bacteria like S. aureus (Figure 5.1). 
 RNase T2 in health and disease 
As RNase T2 is the only member of the RNase T2 superfamily found in humans it strongly 
suggests a non-redundant function in our body. Thus, it is not very surprising that Loss-of-
function mutations within the human RNASET2 gene cause diseases. Patients with this defect 
suffer from cystic leukoencephalopathy mimicking a neonatally asymptomatic congenital 
cytomegalovirus (CMV) brain infection. The MRI (magnetic resonance imaging) pattern is 
indistinguishable from CMV infection and show multifocal white matter lesions and in some 
cases calcification. As a result, patients manifest with impairment, spasticity and in rare cases 
also epilepsy (Henneke et al., 2009). Therefore, it is tempting to assume RNase T2 deficiency 
and Aicardi-Goutières syndrome (AGS) share a similar pathomechanism (Rice et al., 2017). 
Patients with AGS have mutations in genes like TREX1, RNase H2, SAMHD1 and ADAR1 leading 





accumulation of nucleic acids inside the cell and thus to unwanted activation of PRR, resulting 
in autoinflammation (Crow and Manel, 2015). At first glance this may seem counterintuitive 
as our results indicate a pro-inflammatory role of RNase T2. However, if we take a closer look 
at the impact of RNase T2 deficiency on cells, we can explain the hypothesis: under 
physiological conditions RNase T2 is generating ligands specifically activating TLR8, leading to 
a pro-inflammatory immune response. Even though this pathway cannot be engaged in the 
absence of RNase T2 it is likely, that loss-of-function mutations lead to RNA accumulation 
inside the endolysosome. Over time the accumulated RNA can leak into the cytoplasm 
activating cytoplasmic RNA sensors. This would suggest, that due to constant RNA degradation 
RNase T2 has an important function in nucleic acid homeostasis. To prevent continuous TLR8 
activation under steady state conditions, it is likely that a certain RNA threshold has to be 
reached for receptor activation. Furthermore, the activity of either RNase T2 or TLR8 could 
also be modulated by RNA modifications like they can be found in tRNA or rRNA (Pereira et 
al., 2018; Taoka et al., 2018). Interestingly, a similar mechanism was proposed for DNase II, 
which is also located in the endolysosomal compartment and acts upstream of TLR9. On the 
one hand, the enzyme is published to digest dsDNA, to generate appropriate ligands for TLR9 
(Chan et al., 2015), whereas on the other hand, lack of DNase II leads to DNA leakage into the 
cytoplasm and the subsequent activation of the cGAS-STING pathway (Ahn et al., 2012; Gao 
et al., 2015). This underlines the importance of a tightly balanced nucleic acid metabolism. 
Intriguingly, a study using zebrafish as animal model showed, that RNase T2 deficiency leads 
to RNA accumulation in the lysosomes of cerebral neurons and white matter lesions. They 
concluded, that loss of RNase T2 function is associated with lysosomal storage diseases (Haud 
et al., 2011). This strongly suggests an inhibitory role of RNase T2 in autoinflammatory 
diseases by preventing RNA accumulation inside the endolysosomal compartment. All in all, it 
seems like RNase T2 needs to be tightly balanced between its pro-inflammatory role in TLR8 
activation and its potential anti-inflammatory role by RNA degradation. However, this would 
also render lysosomal nucleases protected against pathogen encoded immune modulators, as 
their downregulation would lead to the activation of cytosolic PRR. 
 The BLaER1 cell culture system 
Monocytes and macrophages play an important role in the investigation of the properties and 
function of the innate immune system. This is due to their crucial role to induce and model 
the immune response. Commonly, murine macrophages are used to study innate immune 
pathways as loss-of-function studies can be performed in this species. Human myeloid cells 
can, however, be used for in vitro studies. This becomes especially important if proteins like 





like THP-1, however, only mimic human primary myeloid cells to a certain degree (Gaidt et al., 
2018). A better model for this purpose is the BLaER1 trans-differentiation system. These cells 
can easily be genetically edited by the CRISPR/Cas9 system in their B-cell state. Afterwards 
they can be differentiated into monocytes/macrophages and used to study pathways of the 
innate immune system. Even though the BLaER1 cell line provides an excellent platform to 
investigate diverse immune pathways it also has limitations. One of them is the differing gene 
expression of lysosomal RNases between differentiated BLaER1 cells and primary human 
monocytes. Whereas RNase T2 is expressed in both cell types, the expression of enzymes from 
the RNase A family differs. While BLaER1 cells express huge amounts of RNase 1 there is 
basically no expression in primary monocytes. For RNase 2 it is the other way around whereas 
RNase 6 can be found in both cell types (Figure 4.3). For THP-1 cells on the other hand the 
predominantly expressed RNase is RNase 2. The differential expression of RNase A encoding 
genes could especially influence the release of uridine from RNA fragments as the enzyme 
class was published to cleave downstream of pyrimidines (Lu et al., 2018; Raines, 1998). To 
this end, it is likely, that the first pocket ligand for TLR8 is generated by different enzymes from 
the RNase A family, depending on which cell type is used. Cell culture models always try to 
mimic primary cells, however, there are always differences that have to be considered. 
 Our work in the context of recent publications 
Recently Ostendorf and colleagues published their findings on a similar topic (Ostendorf et al., 
2020). Even though they confirmed that RNase T2 is critically required for TLR8 activation, 
there are some differences between the two studies. First, they propose that RNase 2 is 
equally important for RNA degradation upstream of TLR8. Yet this is only true for THP-1 cells, 
as they could reproduce our result in BLaER1 cells showing a complete dependence on 
RNase T2 upon RNA40S stimulation. This result can most likely be explained by the RNase 
expression pattern of the different cell lines. According to our data, robust TLR8 activation can 
only occur in the presence of RNase T2, generating ligands for the second binding pocket and 
a member of the RNase A family needed for uridine release. A closer look at RNase expression 
levels in different cell types (Ostendorf et al., 2020) shows high amounts of RNase T2, RNase 1 
and RNase 6 in differentiated BLaER1 cells, whereas THP-1 cells mainly express RNase T2 and 
RNase 2. Thus, it is not surprising that RNase 2 is also critical to THP-1 cells being the only 
RNase from the RNase A family expressed in these cells. In BLaER1 cells on the other hand we 
could not observe reduced stimulation in the absence of RNase 2, which is most likely due to 
redundant cleavage patterns between RNase A type enzymes. A key difference of the two 
studies is the proposed cleavage pattern of RNase T2. In contrast to our results, suggesting 





proposing a much broader specificity. In line with our findings they state that RNase T2 has a 
quite strong preference for uridine in the second pocket, but they propose it also accepts 
adenosine to some extent. Strikingly, it is claimed that RNase T2 has basically no preference 
at its first binding position. For instance, they show that RNase T2 is capable of cleaving 
poly(U). Indeed, we have also observed that high concentrations of poly(U) can stimulate 
TLR8, however, this is largely independent of RNase T2 (data not shown). In light of our data 
we hypothesize that poly(U) is degraded via RNase A family members overwhelming the first 
pocket of TLR8, bypassing the need of the second pocket. This situation, however, does not 
reflect the natural role of TLR8 in detecting the presence of complex RNA molecules, for which 
both binding pockets are required (Tanji et al., 2015). Interestingly, they used 
phosphorothioate stabilized RNA for LC/MS analysis of the cleavage site, although 
phosphodiester RNA was used throughout most of their paper. This might result in difficulties 
determining the relative amount of found fragments caused by diastereomers. As such, every 
phosphorothioate linkage added to an RNA molecule increases the number of possible 
diastereomers by a factor of two. Consequently, a ORN with 19 phosphorothioate linkages 
consists of 219 diastereomers that produce distinct peaks in HPLC analysis. Therefore, 
whenever possible, we tried to employ phosphodiester linked ORNs for experiments involving 
HPLC. In addition to ssRNA40 and 9.2s RNA, Ostendorf and colleagues also included R2152 
(CGCGUGCGCAGAAGCGCGCGC) into their cleavage analysis. R2152 is a hairpin ON with a GU 
dinucleotide in the double stranded area and the sequence AGAA in the single stranded loop 
(base pairing nucleotides are underlined, whereas the wobble G:U pair is shown in bold). Of 
note, the U residue of the single GU dinucleotide is paired with a G, forming a wobble base 
pair. The major cleavage sites they propose are between the GU dinucleotide and AG as well 
as AA inside the single stranded loop. This indicates a preference of RNase T2 for GU – 
accessible due to the wobble base pairing and the single stranded stretch. This is in line with 
our results, showing that RNase T2 has a bias towards ssRNA. To this end, it is conceivable that 
RNase T2 is showing off-target cleavage at the AG and AA site as they are located inside the 
single stranded stretch of the ON. To, therefore, unequivocally identify the true cleavage 
pattern of RNase T2 it might be best to only take ssRNA molecules in order to avoid that the 
results get blurred by the influence of ds versus ssRNA. However, in their cleavage analysis 
this bias was not accounted for. Unfortunately, due to technical issues, they did not include 
the ONs ORN002 ((UUA)6UU) and ORN006 ((UUG)6UU) to their cleavage analysis, even though 
these would have been the perfect choice to investigate the preference of RNase T2 between 
G/A-U and U-U cleavage. Interestingly, it is shown that incubation of RNase T2 with either of 
these ONs mainly led to RNA fragments with a length of a multiple of three, which would be 
consistent with a cleavage between GU or AU. Furthermore, Ostendorf et al. proposed that 





preference for ssRNA. Although they saw cleavage of 9.2s dsRNA there was a clear quality 
difference as the single stranded 9.2s RNA was digested more efficiently at the same enzyme 
concentration. This points into the direction that RNase T2 having a preference for ssRNA but 
is also capable of digesting dsRNA at higher concentrations. It is important to note that our 
findings only identified the major cleavage site of RNase T2. Like most enzymes it is highly 
likely that under specific circumstances like high protein concentration or the lack of the target 
sequence, off-target effects can be seen, especially if very sensitive readout methods are used. 
Ultimately, the two papers differ in several points. However, some of the differences like the 
need of RNase 2 in THP-1 cells, might be resolved by additional experiments demonstrating 
that RNase A enzymes in BLaER1 cells are redundant. Where the two studies diverge is the 
cleavage pattern of RNase T2. However, as outlined above, these presumptive differences are 







TLR8 is one of the highest-expressed pattern recognition receptors in the myeloid system, yet 
its mode of action is only poorly understood. This is mainly due to the lack of functional TLR8 
in mice, where only the closely related receptor TLR7 can be activated under physiological 
conditions. TLR8 belongs to the family of toll-like receptors and is together with TLR3, TLR7 
and TLR9 located inside the endolysosomal compartment. Whereas TLR9 is sensing CpG-DNA 
and TLR3 dsRNA, the ligand for both TLR7 and TLR8 is ssRNA. Upon activation of TLR7/8 the 
adaptor protein MyD88 is recruited, leading to downstream signaling and the activation of the 
NF-kB as well as the interferon pathway. Several years ago, the crystal structure of human 
TLR8 was solved showing that the receptor is composed of a cytoplasmic TIR domain, one 
transmembrane domain and a lysosomal domain built up by leucine-rich repeats (LRR). Inside 
the LRR domain a flexible structure called Z-loop is located, which has to be cleaved to obtain 
mature TLR8. Furthermore, the crystal structure revealed two distinct RNA binding pockets 
located inside the LRR domain, however, it remained elusive how theses short RNA ligands 
are formed in cellulo in the context of sensing complex RNA molecules. 
In this study we set out to investigate TLR8 ligand generation and its activation mechanism. A 
systematic gene targeting approach of endolysosomal RNases revealed RNase T2 as a non-
redundant upstream component of TLR8-dependent RNA recognition. The enzyme is critically 
required to break down complex RNA molecules into small fragments, rendering them 
detectible for TLR8. RNase T2 belongs to the RNase T2 superfamily and is the only 
representative found in humans. Even though, several other RNases of the RNase A family are 
present in the endolysosomal compartment, RNase T2 is due to its distinct cleavage pattern 
critically required for TLR8 ligand generation. Its preferential cleavage between purine and 
uridine residues leads to the generation of purine-2ʹ,3ʹ-cyclophosphate-terminated 
oligoribonucleotides, which can encounter the second binding pocket of TLR8. Furthermore, 
RNase T2 is critically involved in the release of catabolic uridine, binding to the first pocket of 
TLR8. However, our experiments show, that even though the occupation of the first pocket by 
chemical compounds like R848 is sufficient for TLR8 activation, the sole increase of uridine 
seen in the context of a complex RNA molecule stimulation is not enough to trigger TLR8 
signaling. To this end, RNase T2 generated purine-2ʹ,3ʹ-cyclophosphate-terminated fragments 
are critically involved in TLR8 signaling by allosterically controlling uridine binding, which 
ultimately leads to receptor activation. Of note, even though the 2’,3’- cyclophosphate 
configuration did enhance TLR8 activity it was neither required nor sufficient, as also purine 
terminated fragments with an open phosphate, or a hydroxyl group were immunostimulatory. 
Finally, we could show, that the RNase T2-TLR8 route is involved in sensing pathogens like 
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8 List of abbreviation 
 
8-OHdG 8-hydroxy-2' -Deoxyguanosine 
8-OHG 8-Hydroxyguanosine 
A Adenosine 
ACS  Aicardi-Goutières syndrome 
AIM2 Absent In Melanoma 2 
bp Base pair 
C Cytidine 
cGAMP Cyclic GMP-AMP 
cGAS Cyclic GMP-AMP synthase 
CLRs C-type lectin receptors 
CMV  Cytomegalovirus 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CSFV Classical swine fever virus 
CXorf21 Chromosome X Open Reading Frame 21 
dA Deoxyadenosine 
DAMP Damage-associated molecular pattern 
dC Deoxycytidine 
DCs Dendritic cells 
DD Death domain 
dG Deoxyguanosine 
DNA Deoxyribonucleic acid 
dNTPs Deoxynucleoside triphosphates 
ds Double stranded 
dT Deoxythymidine 
ELISA Enzyme-linked Immunosorbent Assay 
ER Endoplasmic reticulum 
EtOH Ethanol 
FACS Fluorescence-activated cell sorting 
FCS Fetal cow serum 
G Guanosine 
GPCR G protein-coupled receptors 






HIV Human immunodeficiency virus 
HSCs Hematopoietic stem cells 
IFN Interferon 
IKK Inhibitor of nuclear factor kappa-B kinase 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IRAK IL-1 receptor-activated protein kinase 
IRF Interferon regulatory factor 
JAK  Janus kinase  
LGP2 Laboratory of genetics and physiology 2 
LPS Lipopolysaccharide 
LRR Leucine-rich repeat 
M-CSF Macrophage colony-stimulating factor 
MAC Membrane attack complex 
MAL MyD88 adaptor like protein 
MAPK Mitogen-activated protein kinase 
MAVS Mitochondrial antiviral-signaling protein 
MDA5 Melanoma differentiation-associated protein 5 
MHC Major histocompatibility complex 
MLKL mixed lineage kinase domain-like protein 
MRI Magnetic resonance imaging 
MyD88 Myeloid differentiation factor 88 
NADPH nicotinamide adenine dinucleotide phosphate 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLRP NOD-, LRR- and pyrin domain-containing protein 
NLRs NOD like receptors 
OAS 2ʹ-5ʹ-oligoadenylate synthetase 
ONs Oligoribonucleotides 
PAMP Pathogen associated molecular pattern 
PCR Polymerase chain reaction 
PMA Phorbol 12-myristate 13-acetate 
pR Poly-L-arginine 
PRR Pattern recognition receptors 
RIG-I Retinoic acid-inducible gene I 
RIPK Receptor-interacting serine/threonine-protein kinase 
RLRs RIG-I like receptors 





Rnase L Ribonuclease L 
RNP Ribonucleoprotein 
ROS Reactive oxygen species 
rRNA Ribosomal ribonucleic acid 
SAMHD1 SAM domain and HD domain-containing protein 1 
SLC15A4 Central nervous system 
ss Single stranded 
STAT Signal transducers and activators of transcription 
STING  Stimulator of interferon genes 
T Thymidine 
TAK1 transforming growth factor b activated protein kinase 1 
TASL TLR adaptor interacting with SLC15A4 on the lysosome 
TBK1 TANK-binding kinase1 
TIR domain Toll/Interleuchin-1 domain 
TLR Toll-like receptors 
TNF Tumor necrosis factor 
TRAF tumor necrosis factor receptor associated factor 
TRAF tumor necrosis factor receptor associated factor 
TRIF TIR-domain-containing adapter-inducing interferon-β 
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